Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Number of items: 376.

Milne, Paul, Wilhelm-Benartzi, Charlotte, Grunwald, Michael R., Bigley, Venetia, Dillon, Richard, Freeman, Sylvie D., Gallagher, Kathleen, Publicover, Amy, Pagan, Sarah, Marr, Helen, Jones, Gail L., Dickinson, Anne M., Grech, Angela, Burnett, Alan K., Russell, Nigel H., Levis, Mark, Knapper, Steven and Collin, Matthew 2019. Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances 3 (20) , pp. 3052-3061. 10.1182/bloodadvances.2019000197
file

Burnett, Alan K, Das Gupta, Emma, Knapper, Steve, Khwaja, Asim, Sweeney, Marion, Kjeldsen, Lars, Hawkins, Timothy, Betteridge, Sophie E., Cahalin, Paul, Clark, Richard E., Hills, Robert K. and Russell, Nigel H. 2018. Addition of the mammalian target of rapamycin inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial. Haematologica 103 (10) , pp. 1654-1661. 10.3324/haematol.2018.189514
file

Russell, Nigel, Burnett, Alan, Hills, Robert, Betteridge, Sophie, Dennis, Mike, Jovanovic, Jelena, Dillon, Richard and Grimwade, David 2018. Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. Blood 132 (13) , pp. 1452-1454. 10.1182/blood-2018-05-851824
file

Burnett, Alan K., Hills, R K, Nielsen, O J, Freeman, S, Ali, A, Cahalin, P, Hunter, A, Thomas, Ian and Russell, N H 2018. A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia 32 , pp. 2693-2714. 10.1038/s41375-018-0148-3

Knapper, Steven, Russell, Nigel, Gilkes, Amanda, Hills, Robert K., Gale, Rosemary E., Cavenagh, James D., Jones, Gail, Kjeldsen, Lars, Grunwald, Michael R., Thomas, Ian, Konig, Heiko, Levis, Mark J. and Burnett, Alan K. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129 (9) , pp. 1143-1154. 10.1182/blood-2016-07-730648
file

Burnett, Alan Kenneth, Russell, N. H., Hills, Robert Kerrin, Kell, J., Nielsen, O. J., Dennis, M., Cahalin, P., Pocock, C., Ali, S., Burns, Sarah, Freeman, S., Milligan, D. and Clark, R. E. 2017. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia 31 (2) , pp. 310-317. 10.1038/leu.2016.225
file

Chilton, L, Harrison, C J, Ashworth, I, Murdy, D, Burnett, A K, Grimwade, D, Moorman, A V and Hills, R K 2017. Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia. Leukemia 31 (5) , pp. 1234-1237. 10.1038/leu.2017.37
file

Khan, N, Hills, Robert, Virgo, P, Couzens, S, Clark, N, Gilkes, Amanda, Richardson, P, Knapper, Steven, Grimwade, D, Russell, N H, Burnett, Alan and Freeman, S D 2016. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia 31 (5) , pp. 1059-1068. 10.1038/leu.2016.309
file

Burnett, Alan Kenneth, Cavenagh, J., Russell, N., Hills, Robert Kerrin, Kell, J., Jones, G., Nielsen, O. J., Khwaja, A., Thomas, Ian and Clark, R. 2016. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial. Haematologica 101 (6) , pp. 724-731. 10.3324/haematol.2016.141937
file

Dickson, Glenda J., Bustraan, Sophia, Hills, Robert Kerrin, Ali, Akbar, Goldstone, Anthony H., Burnett, Alan, Linch, David C. and Gale, Rosemary E. 2016. The value of molecular stratification for CEBPA DM and NPM1 MUT FLT3 WT genotypes in older patients with acute myeloid leukaemia. British Journal of Haematology 172 (4) , pp. 573-580. 10.1111/bjh.13873

Raja, Meera, Zverev, Matthew, Seipel, Katja, Williams, Geraint T., Burnett, Alan Kenneth, Clarke, Alan Richard and Shaw, Paul 2015. Assessment of the in vivo activity of PI3K and MEK inhibitors in genetically defined models of colorectal cancer. Molecular Cancer Therapeutics 14 (10) , pp. 2175-2186. 10.1158/1535-7163.MCT-15-0223

Lazenby, Michelle, Hills, Robert Kerrin, Burnett, Alan Kenneth and Zabkiewicz, Joanna 2015. The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leukemia Research 39 (6) , pp. 617-624. 10.1016/j.leukres.2015.03.016
file

Hole, Paul Spencer, Zabkiewicz, Joanna, Munje, Chinmay, Newton, Zarabeth, Pearn, Lorna, White, Paul Charles, Marquez, Nuria, Hills, Robert Kerrin, Burnett, Alan Kenneth, Tonks, Alex and Darley, Richard Lawrence 2013. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 122 (19) , pp. 3322-3330. 10.1182/blood-2013-04-491944

Burnett, Alan Kenneth, Russell, Nigel H., Hills, Robert Kerrin, Hunter, Ann E., Kjeldsen, Lars, Yin, John Yin., Gibson, Brenda E. S., Wheatley, Keith and Milligan, Donald 2013. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the Medical Research Council AML15 trial. Journal of Clinical Oncology 31 (27) , pp. 3360-3368. 10.1200/JCO.2012.47.4874

Allen, C., Hills, Robert Kerrin, Lamb, K., Evans, C., Tinsley, S., Sellar, R., O'Brien, M., Yin, J. L., Burnett, A. K., Linch, D. C. and Gale, R. E. 2013. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia 27 (9) , pp. 1891-1901. 10.1038/leu.2013.186

Burnett, Alan Kenneth, Russell, N. H., Hunter, A. E., Milligan, D., Knapper, Steven, Wheatley, K., Yin, J., McMullin, M. F., Ali, S., Bowen, D. and Hills, Robert Kerrin 2013. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 122 (8) , pp. 1384-1394. 10.1182/blood-2013-04-496596

Green, Claire L., Tawana, Kiran, Hills, Robert Kerrin, Bodor, Csaba, Fitzgibbon, Jude, Inglott, Sarah, Ancliff, Phil, Burnett, Alan Kenneth, Linch, David C. and Gale, Rosemary E. 2013. GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations. British Journal of Haematology 161 (5) , pp. 701-705. 10.1111/bjh.12317

Burnett, Alan Kenneth and Hills, Robert Kerrin 2013. No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard Medical Research Council induction chemotherapy - Reply [Letter]. Journal of Clinical Oncology 31 (13) , pp. 1700-1701. 10.1200/JCO.2013.48.6571

Craddock, C., Quek, L., Goardon, N., Freeman, S., Siddique, S., Raghavan, M., Aztberger, A., Schuh, A., Grimwade, D., Ivey, A., Virgo, P., Hills, Robert Kerrin, McSkeane, T., Arrazi, J., Knapper, Steven, Brookes, C., Davies, B., Price, A., Wall, K., Griffiths, M., Cavenagh, J., Majeti, R., Weissman, I., Burnett, Alan Kenneth and Vyas, P. 2013. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 27 (5) , pp. 1028-1036. 10.1038/leu.2012.312

Nacheva, Ellie P., Grace, Colin D., Brazma, Diana, Gancheva, Katya, Howard-Reeves, Julie, Rai, Lena, Gale, Rosemary E., Linch, David C., Hills, Robert Kerrin, Russell, Nigel, Burnett, Alan Kenneth and Kottaridis, Panagiotis D. 2013. Does BCR/ABL1 positive acute myeloid leukaemia exist? British Journal of Haematology 161 (4) , pp. 541-550. 10.1111/bjh.12301

Walsby, Elisabeth Jane, Lazenby, Michelle, Pepper, Christopher John, Knapper, Steven and Burnett, Alan Kenneth 2013. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. British Journal of Haematology 161 (1) , pp. 57-67. 10.1111/bjh.12215

Burnett, Alan Kenneth, Goldstone, Anthony, Hills, Robert Kerrin, Milligan, Donald, Prentice, Archie, Yin, John, Wheatley, Keith, Hunter, Ann and Russell, Nigel 2013. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. Journal of Clinical Oncology 31 (10) , pp. 1293-1301. 10.1200/JCO.2011.40.5977

Burnett, Alan Kenneth, Hills, Robert Kerrin, Grimwade, D., Jovanovic, J. V., Craig, J., McMullin, M. F., Kell, J., Wheatley, K., Yin, J. A. L., Hunter, A., Milligan, D and Russell, N. H. 2013. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial. Leukemia 27 (4) , pp. 843-851. 10.1038/leu.2012.360

Ling, Victoria, Burnett, Alan Kenneth, Bradstock, Ken, Seymour, John F., Hills, Robert Kerrin and Wei, Andrew 2013. Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy. British Journal of Haematology 160 (6) , pp. 861-863. 10.1111/bjh.12178

Morgan, Rhys G., Pearn, Lorna, Liddiard, Kate, Pumford, Sara Louise, Burnett, Alan Kenneth, Tonks, Alex and Darley, Richard Lawrence 2013. γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin. Leukemia 27 (2) , pp. 336-343. 10.1038/leu.2012.221
file

McLornan, Donal, Hay, Jodie, McLaughlin, Kirsty, Holohan, Caitriona, Burnett, Alan Kenneth, Hills, Robert Kerrin, Johnston, Patrick G., Mills, Ken Ian, McMullin, Mary Frances and Longley, Daniel B. 2013. Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. British Journal of Haematology 160 (2) , pp. 188-198. 10.1111/bjh.12108

Burnett, Alan Kenneth, Hills, Robert Kerrin, Hunter, A. E., Milligan, D., Kell, W. J., Wheatley, K., Yin, J., McMullin, M. F., Dignum, H., Bowen, Derrick John and Russell, Nicholas H. 2013. The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia 27 , pp. 75-81. 10.1038/leu.2012.229

Burnett, Alan K. 2013. The challenge of AML in older patients. Mediterranean Journal of Hematology and Infectious Diseases 5 (1) , p. 2013038. 10.4084/mjhid.2013.038

Daud, Siti Sarah, Pumford, Sara L, Gilmour, Marie N., Gilkes, Amanda F., Burnett, Alan Kenneth, Hills, Robert Kerrin, Tonks, Alex and Darley, Richard Lawrence 2012. Identification of the Wnt signalling protein, TCF7L2 as a significantly overexpressed transcription factor in AML [Abstract]. Blood 120 (21) , 1281.

Bradbury, Charlotte Ann, Ward, Janice, Vyas, Paresh, Russell, Higel H., Grimwade, David, Hills, Robert Kerrin, Burnett, Alan Kenneth, Craddock, Charles F. and Freeman, Sylvie 2012. Residual disease detection by flow cytometry predicts risk of relapse and overall survival in patients with Acute Myeloid Leukemia following reduced intensity- and Myeloablative- Allogeneic Hematopoietic Cell Transplantation [Abstract]. Blood -New York- 120 (21)

Russell, Nigel H., Hills, Robert Kerrin, Kjeldsen, Lars, Yin, John L., Craddock, Charles and Burnett, Alan Kenneth 2012. Reduced intensity transplant may improve survival in patients over the age of 40, especially if a sibling donor Is Used: pooled analysis of 2454 patients and 407 transplants in the UK NCRI AML15 and AML16 trials [Abstract]. Blood -New York- 120 (21)

Burnett, Alan Kenneth, Russell, Nigel H., McMullin, Mary Frances, Kell, Jonathan, Ali, Sahra, Moreton, Paul, Wei, Andrew H., Kjeldsen, Lars and Hills, Robert Kerrin 2012. A randomised comparison of Clofarabine versus low dose Ara-C as first line treatment for older patients with AML [Abstract]. Blood -New York- 120 (21)

Burnett, Alan Kenneth, Russell, Nigel H., Kell, Jonathan, Kjeldsen, Lars, Milligan, Donald, Cahalin, Paul and Hills, Robert Kerrin 2012. A comparison of Daunorubicin/Ara-C (DA) versus Daunorubicin/Clofarabine (DClo) and two versus three courses of total treatment for older patients with AML and high risk MDS: results of the UK NCRI AML16 Trial [Abstract]. Blood -New York- 120 (21)

Yin, John A. Liu, O'Brien, Michelle A., Hills, Robert Kerrin, Daly, Sarah B., Wheatley, Keith and Burnett, Alan Kenneth 2012. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 120 (14) , pp. 2826-2835. 10.1182/blood-2012-06-435669

Burnett, Alan Kenneth, Russell, Nigel H., Hills, Robert Kerrin, Kell, Jonathan, Freeman, Sylvie, Kjeldsen, Lars, Hunter, Ann E., Yin, John, Craddock, Charles F., Dufva, Inge Hoegh, Wheatley, Keith and Milligan, Donald 2012. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Journal of Clinical Oncology 30 (32) , pp. 3924-3931. 10.1200/JCO.2012.42.2964

Coles, Steven, Hills, Robert Kerrin, Wang, Edward Chung Yern, Burnett, Alan Kenneth, Man, Stephen Tzekwung, Darley, Richard Lawrence and Tonks, Alex 2012. Expression of CD200 on AML blasts directly suppresses memory T-cell function [Letter]. Leukemia 26 (9) , pp. 2148-2151. 10.1038/leu.2012.77
file

Coles, Steven, Hills, Robert Kerrin, Wang, Edward Chung Yern, Burnett, Alan Kenneth, Man, Stephen Tzekwung, Darley, Richard Lawrence and Tonks, Alex 2012. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells [Letter]. Leukemia 26 (9) , pp. 2146-2148. 10.1038/leu.2012.75
file

Burnett, Alan Kenneth, Russell, Nigel H., Culligan, Dominic, Cavanagh, Jamie, Kell, Jonathan, Wheatley, Keith, Virchis, Andra, Hills, Robert Kerrin and Milligan, Donald 2012. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. British Journal of Haematology 158 (4) , pp. 519-522. 10.1111/j.1365-2141.2012.09165.x

Grimwade, David and Burnett, Alan Kenneth 2012. Getting to the heart of improving outcomes for patients with acute promyelocytic leukemia. Oncology-New York 26 (7) , pp. 647-649.

Walsby, Elisabeth Jane, Pearce, Laurence, Burnett, Alan Kenneth, Fegan, Christopher Daniel and Pepper, Christopher John 2012. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget 3 (5) , pp. 525-534.

Burnett, Alan Kenneth, Freeman, S., Hills, Robert Kerrin, Hunter, A. E., Milligan, D. W., Kell, W. J., Wheatley, K., Yin, J. A. L., Ali, S., Kjeldsen, L., Goldstone, A. H., Bowen, D and Russell, N. H. 2012. The addition of gemtuzumab ozogamicin to induction chemotherapy in AML reduces relapse and improves survival in the majority of patients of all ages: the AML15 and 16 trial experience [Abstract]. British Journal of Haematology 157 (S1) , p. 1. 10.1111/j.1365-2141.2012.09071.x

El-Sharkawi, D., Ali, A., Evans, C. M., Hills, Robert Kerrin, Burnett, Alan Kenneth, Linch, D. C. and Gale, R. E. 2012. ASXL1 mutations are infrequent in young patients with primary acute myeloid leukaemia [Abstract]. British Journal of Haematology 157 (S1) , p. 56. 10.1111/j.1365-2141.2012.09071.x

Allen, C. G., Tinsley, S. P., Hills, Robert Kerrin, Evans, C. M., Lamb, K., Sellar, R. S., Sale, M., Yin, J. L., Burnett, Alan Kenneth, Linch, D. C. and Gale, R. E. 2012. The impact of mutant level on clinical outcome in acute myeloid leukaemia differs according to the mutated gene [Abstract]. British Journal of Haematology 157 (S1) , p. 20. 10.1111/j.1365-2141.2012.09071.x

Schenk, Tino, Chen, Weihsu Claire, Göllner, Stefanie, Howell, Louise, Jin, Liqing, Hebestreit, Katja, Klein, Hans-Ulrich, Popescu, Andreea C., Burnett, Alan Kenneth, Mills, Kenneth Ian, Casero, Robert A., Marton, Laurence, Woster, Patrick, Minden, Mark D., Dugas, Martin, Wang, Jean C. Y., Dick, John E., Müller-Tidow, Carsten, Petrie, Kevin and Zelent, Arthur 2012. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia [Letter]. Nature Medicine 18 (4) , pp. 605-611. 10.1038/nm.2661

Liddiard, Kate, Burnett, Alan Kenneth, Darley, Richard Lawrence and Tonks, Alex 2012. RUNX1-ETO deregulates the proliferation and growth factor responsiveness of human hematopoietic progenitor cells downstream of the myeloid transcription factor, MYCT1 [Letter]. Leukemia 26 (1) , pp. 177-179. 10.1038/leu.2011.188
file

Burnett, Alan Kenneth 2012. New induction and postinduction strategies in acute myeloid leukemia. Current Opinion in Hematology 19 (2) , pp. 76-81. 10.1097/MOH.0b013e3283500a92

Coles, Steven, Man, Stephen Tzekwung, Hills, Robert Kerrin, Wang, Edward Chyng Yern, Burnett, Alan Kenneth, Darley, Richard Lawrence and Tonks, Alex 2011. CD200 inhibits memory Th1 cell function in acute myeloid leukaemia (AML)[Abstract]. Immunology 135 (S1) , p. 178. 10.1111/j.1365-2567.2011.03534.x

Knapper, Steven, White, Paul Charles, Levis, Mark J., Hills, Robert Kerrin, Russell, Nigel H. and Burnett, Alan Kenneth 2011. The efficacy of the FLT3 inhibitor Lestaurtinib in AML depends on adequate plasma inhibitory activity (PIA), and is unaffected by rising FLT ligand levels: an update of the NCRI AML15 & 17 trials. Blood -New York- 118 (21) , p. 194.

Mohamedali, Azim M., Hills, Robert Kerrin, Nasser, Erick E., Abdallah, Atiyeh, Shinde, Sneha, Kulasekararaj, Austin G., Gilkes, Amanda F., Lea, Nicholas, Burnett, Alan Kenneth and Mufti, Ghulam J. 2011. Single Nucleotide Polymorphism Array (SNP-A) karyotype is the best predictor of prognosis in normal cytogenetics Acute Myeloid Leukaemia (AML). Blood -New York- 118 (21) , pp. 188-189.

Craddock, Charles F., Goardon, Nicolas, Quek, Lynn, Freeman, Sylvie, Siddique, Shamyla, Raghavan, Manoj, Schuh, Anna, Grimwade, David, Hills, Robert Kerrin, Brookes, Cassandra, Griffiths, Michael, Cavenagh, James D., Majeti, Ravindra, Weissman, Irving L., Burnett, Alan Kenneth and Vyas, Paresh 2011. Quantitation of leukemic stem cell populations predicts clinical outcome in Acute Myeloid Leukaemia. Blood -New York- 118 (21) , p. 292.

Burnett, Alan Kenneth, Hills, Robert Kerrin, Hunter, Ann E., Milligan, Donald, Kell, William J., Wheatley, Keith, Yin, John L., Ali, Sahra, Kjeldsen, Lars, Bowen, David and Russell, Nigel H. 2011. The addition of Gemtuzumab Ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial. Blood -New York- 118 (21) , p. 268.

Allen, C. G., Hills, Robert Kerrin, Evans, C. M., Lamb, K., Sellar, R., Moorman, A. V., Sale, M., Liu-Yin, J. A., Burnett, Alan Kenneth, Linch, D. C. and Gale, R. E. 2011. Mutations in a large cohort of young adult patients with core binding factor acute myeloid leukemia: Impact on outcome and the selection of patients for alternative treatment including transplantation in first complete remission [Abstract]. Blood 118 (21) , p. 193.

Altug, C., Burnett, Alan Kenneth, Caner, E., Dürüst, Y., Elliott, Mark Christopher, Glanville, Roger P. J., Guy, Carol and Westwell, Andrew D. 2011. An efficient one-pot multicomponent approach to 5-amino-7-aryl-8-nitrothiazolo[3,2-a]pyridines. Tetrahedron 67 (49) , pp. 9522-9528. 10.1016/j.tet.2011.10.005

Dawson, Mark A., Prinjha, Rab K., Dittmann, Antje, Giotopoulos, George, Bantscheff, Marcus, Chan, Wai-In, Robson, Samuel C., Chung, Chun-wa, Hopf, Carsten, Savitski, Mikhail M., Huthmacher, Carola, Gudgin, Emma, Lugo, Dave, Beinke, Soren, Chapman, Trevor D., Roberts, Emma J., Soden, Peter E., Auger, Kurt R., Mirguet, Olivier, Doehner, Konstanze, Delwel, Ruud, Burnett, Alan Kenneth, Jeffrey, Phillip, Drewes, Gerard, Lee, Kevin, Huntly, Brian J. P. and Kouzarides, Tony 2011. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478 (7370) , pp. 529-533. 10.1038/nature10509

Hills, Robert Kerrin and Burnett, Alan Kenneth 2011. Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. Blood 118 (9) , pp. 2389-2394. 10.1182/blood-2011-02-337261

Pallis, M, Hills, Robert Kerrin, White, Paul Charles, Grundy, M, Russell, N and Burnett, Alan Kenneth 2011. Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial. Blood Cancer Journal 1 , e23.

Collins, Andrew M., Zabkiewicz, Joanna, Ghiggi, Chiara, Hauser, Jonathan C., Burnett, Alan Kenneth and Mann, Stephen 2011. Tris(8-hydroxyquinolinato)gallium(III)-loaded copolymer micelles as cytotoxic nanoconstructs for cosolvent-free organometallic drug delivery. Small 7 (12) , pp. 1635-1640. 10.1002/smll.201100405

Sato, Takashi, Yang, Xiaochuan, Knapper, Steven, White, Paul Charles, Smith, B. Douglas, Galkin, Steven, Small, Donald, Burnett, Alan Kenneth and Levis, Mark 2011. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 117 (12) , pp. 3286-3293. 10.1182/blood-2010-01-266742

Walsby, Elisabeth Jane, Coles, Steven, Knapper, Steven and Burnett, Alan Kenneth 2011. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica 96 (3) , pp. 393-399. 10.3324/haematol.2010.032680

Walsby, Elisabeth Jane, Lazenby, Michelle, Pepper, Christopher John and Burnett, Alan Kenneth 2011. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia 25 (3) , pp. 411-419. 10.1038/leu.2010.290

Burnett, Alan Kenneth, Hills, Robert Kerrin, Milligan, Donald, Kjeldsen, Lars, Kell, Jonathan, Russell, Nigel H., Yin, John A. L., Hunter, Ann, Goldstone, Anthony H. and Wheatley, Keith 2011. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 Trial. Journal of Clinical Oncology 29 (4) , pp. 369-377. 10.1200/JCO.2010.31.4310

Burnett, Alan Kenneth 2011. The MRC Experience in Older Patients with AML [Abstract]. Annals of Hematology 90 (S1) , pp. 41-42. 10.1007/s00277-011-1158-7

Coles, Steven, Wang, Edward Chung Yern, Man, Stephen Tzekwung, Hills, Robert Kerrin, Burnett, Alan Kenneth, Tonks, Alex and Darley, Richard Lawrence 2011. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25 (5) , pp. 792-799. 10.1038/leu.2011.1

Goardon, Nicolas, Marchi, Emanuele, Atzberger, Ann, Quek, Lynn, Schuh, Anna, Soneji, Shamit, Woll, Petter, Mead, Adam, Alford, Kate A., Rout, Raj, Chaudhury, Salma, Gilkes, Amanda F., Knapper, Steven, Beldjord, Kheira, Begum, Suriya, Rose, Susan, Geddes, Nicola, Griffiths, Mike, Standen, Graham, Sternberg, Alexander, Cavenagh, Jamie, Hunter, Hannah, Bowen, David, Killick, Sally, Robinson, Lisa, Price, Andrew, Macintyre, Elizabeth, Virgo, Paul, Burnett, Alan Kenneth, Craddock, Charles, Enver, Tariq, Jacobsen, Sten Eirik W., Porcher, Catherine and Vyas, Paresh 2011. Coexistence Of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19 (1) , pp. 138-152. 10.1016/j.ccr.2010.12.012

Shah, Anjali, Andersson, Therese, Rachet, Bernard, Burnett, Alan Kenneth and Lambert, Paul 2011. Trends in survival and the proportion cured of adult acute Myeloid Leukaemia in England, 1971–2006:a population-based study [Abstract]. Pediatric Blood and Cancer 57 (5) , p. 823. 10.1002/pbc.23299

Burnett, Alan Kenneth and Hills, Robert Kerrin 2011. Who should be transplanted in first remission of Acute Myeloid Leukaemia? Current Treatment Options in Oncology 12 (4) , pp. 329-340. 10.1007/s11864-011-0169-x

Jenkins, Christopher, Hewamana, Saman, Krige, David, Pepper, Christopher John and Burnett, Alan Kenneth 2011. Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia. Leukemia Research 35 (5) , pp. 677-681. 10.1016/j.leukres.2010.10.030

Burnett, Alan Kenneth, Hills, Robert Kerrin, Hunter, A., Milligan, D., Kell, Jonathan, Wheatley, K., Yin, J., McMullin, M. F., Cahalin, P., Craig, J., Bowen, D. and Russell, N. 2011. The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome. Leukemia 25 (7) , pp. 1122-1127. 10.1038/leu.2011.59

Green, Claire, Evans, Catherine M., Zhao, Lu, Hills, Robert Kerrin, Burnett, Alan Kenneth, Linch, David C. and Gale, Rosemary E. 2011. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 118 (2) , pp. 409-412. 10.1182/blood-2010-12-322479

Burnett, Alan Kenneth, Wetzler, M. and Lowenberg, B. 2011. Therapeutic Advances in Acute Myeloid Leukemia. Journal of Clinical Oncology 29 (5) , pp. 487-494. 10.1200/JCO.2010.30.1820

Kantarjian, H., Schiffer, C. and Burnett, Alan Kenneth 2011. Hematologic Malignancies: Where Do We Stand in 2011? Journal of Clinical Oncology 29 (5) , pp. 473-474. 10.1200/JCO.2010.33.8897

Hehlmann, Rüdiger, Grimwade, David, Simonsson, Bengt, Apperley, Jane, Baccarani, Michele, Barbui, Tiziano, Barosi, Giovanni, Bassan, Renato, Bene, Marie C., Berger, Ute, Buchner, Thomas, Burnett, Alan Kenneth, Cross, Nicolas C. P., de Witte, Theo J. M., Dohner, Hartmut, Dombret, Hervé, Einsele, Hermann, Engelich, Georg, Foa, Robin, Fonatsch, Christa, Gokbuget, Nicola, Gluckman, Elaine, Gratwohl, Alois, Guilhot, Francois, Haferlach, Claudia, Haferlach, Thorsten, Hallek, Michael, Hasford, Jörg, Hochhaus, Andreas, Hoelzer, Dieter, Kiladjian, Jean-Jaques, Labar, Boris, Ljungman, Per, Mansmann, Ulrich, Niederwieser, Dietgar, Ossenkoppele, Gert, Ribera, José M., Rieder, Harald, Serve, Hubert, Schrotz-King, Petra, Sanz, Miguel A. and Saussele, Susanne 2011. The European LeukemiaNet: achievements and perspectives. Haematologica 96 (1) , pp. 156-162. 10.3324/haematol.2010.032979

Mohamedali, A., Hills, Robert Kerrin, Nasser, E. E., Abdallah, A., Kulasekararaj, A. G., Gilkes, Amanda F., Lea, N., Burnett, Alan Kenneth and Mufti, G. J. 2010. Prognostic significance of cryptic genomic aberrations in AML with normal karyotype [Abstract]. Blood 116 (21) , p. 1125.

Pallis, M., White, Paul Charles, Hills, Robert Kerrin, Grundy, M., Russell, N. H. and Burnett, Alan Kenneth 2010. Analysis of the interaction of induction regimens with P-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 Trial [Abstract]. Blood 116 (21) , p. 1123.

Freeman, S., Hills, Robert Kerrin, Virgo, P., Couzens, Stephen, Lowdell, M. W., McNamara, C. J., White, Paul Charles and Burnett, Alan Kenneth 2010. Detection of immunophenotypic residual disease after induction therapy is an independent prognostic factor for duration of remission in older AML patients treated intensively [Abstract]. Blood 116 (21) , pp. 1118-1119.

Zabkiewicz, Joanna, Pearn, Lorna, Hills, Robert Kerrin, Morgan, Rhys G., Burnett, Alan Kenneth, Tonks, Alex and Darley, Richard Lawrence 2010. PDK1 overexpression in acute myeloid leukemia; Clinical significance and potential as a therapeutic target [Abstract]. Blood 116 (21) , pp. 892-893.

Wei, A. H., Sadawarte, S., Catalano, J., Hills, Robert Kerrin, Avery, S., Patil, S. S., Burnett, Alan Kenneth and Spencer, A. 2010. A phase Ib study Combining the mTOR inhibitor everolimus (RAD001) with low-dose cytarabine In untreated elderly AML [Abstract]. Blood 116 (21) , pp. 1351-1352.

Morgan, Rhys Gareth, Pearn, Lorna, Liddiard, Kate, Hills, Robert Kerrin, Burnett, Alan Kenneth, Tonks, Alex and Darley, Richard Lawrence 2010. Distinct regulation of beta- and gamma-Catenin throughout hematopoietic development contrasts with their cooperative roles in acute myeloid leukemia [Abstract]. Blood 116 (21) , 1573.

Coles, Steven, Man, Stephen Tzekwung, Hills, Robert Kerrin, Wang, Edward Chung Yern, Burnett, Alan Kenneth, Darley, Richard Lawrence and Tonks, Alex 2010. Over-expression of CD200 un acute myeloid leukemia mediates the expansion of regulatory T-lymphocytes and directly inhibits natural killer cell tumor immunity [Abstract]. Blood 116 (21) , p. 218.

Stringaris, K., Barrett, A. J., Hills, Robert Kerrin, Linch, D. C., Gale, R., Allen, C., Garland, P., Sargent, R., de Lavallade, H., Alsuliman, A., Khoder, A., Gabriel, I. H., Sekine, T., Burnett, Alan Kenneth, Rezvani, K. and Apperley, J. F. 2010. A distinct signature of natural killer cell KIR gene frequencies in secondary AML compared with de novo AML and normal controls. Blood 116 (21) , pp. 711-712.

Green, C. L., Evans, C. M., Hills, Robert Kerrin, Zhao, L., Burnett, Alan Kenneth, Linch, D. C. and Gale, R. 2010. Younger adult acute myeloid leukemia (AML) patients with IDH2-R140 mutations have a significantly better prognosis than those with either IDH2-R172 or IDH1 mutations [Abstract]. Blood 116 (21) , p. 50.

Green, Claire L., Evans, Catherine M., Hills, Robert Kerrin, Burnett, Alan Kenneth, Linch, David C. and Gale, Rosemary E. 2010. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116 (15) , pp. 2779-2782. 10.1182/blood-2010-02-270926

Grimwade, David, Hills, Robert Kerrin, Moorman, Anthony V., Walker, Helen, Chatters, Stephen, Goldstone, Anthony H., Wheatley, Keith, Harrison, Christine J. and Burnett, Alan Kenneth 2010. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116 (3) , pp. 354-365. 10.1182/blood-2009-11-254441

Grimwade, D., Hills, Robert Kerrin, Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J. and Burnett, Alan Kenneth 2010. Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials [Abstract]. British Journal of Haematology 149 (S1) , p. 17. 10.1111/j.1365-2141.2010.08116.x

Liddiard, Kate, Hills, Robert Kerrin, Burnett, Alan Kenneth, Darley, Richard Lawrence and Tonks, Alex 2010. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene 29 (13) , pp. 2005-2012. 10.1038/onc.2009.462

Hole, Paul Spencer, Pearn, Lorna, Tonks, Amanda Jayne, James, Philip Eurig, Burnett, Alan Kenneth, Darley, Richard Lawrence and Tonks, Alex 2010. Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells. Blood 115 (6) , pp. 1238-1246. 10.1182/blood-2009-06-222869

Burnett, Alan Kenneth, Hills, Robert Kerrin, Green, C., Jenkinson, S., Koo, K., Patel, Y., Guy, Carol, Gilkes, Amanda F., Milligan, D.W., Goldstone, A.H., Prentice, A.G., Wheatley, K., Linch, D. C. and Gale, R. E. 2010. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115 (5) , pp. 948-956. 10.1182/blood-2009-08-236588

Grimwade, David, Jovanovic, Jelena V., Hills, Robert Kerrin, Solomon, Ellen, Lo-Coco, Francesco, Wheatley, Keith and Burnett, Alan Kenneth 2010. How should we prevent hematologic relapse of acute promyelocytic leukemia? Reply [Letter]. Journal of Clinical Oncology 28 (4) , E63-E64. 10.1200/JCO.2009.24.9995

Burnett, Alan Kenneth, Hills, Robert Kerrin, Milligan, Donald W., Goldstone, Anthony H., Prentice, Archibald G., McMullin, Mary-Frances, Duncombe, Andrew, Gibson, Brenda and Wheatley, Keith 2010. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. Journal of Clinical Oncology 28 (4) , pp. 586-595. 10.1200/JCO.2009.22.9088

Walsby, Elisabeth Jane, Pratt, G., Hewamana, Saman, Crooks, P. A., Burnett, Alan Kenneth, Fegan, Christopher Daniel. and Pepper, Christopher John 2010. The NF- B inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. Molecular Cancer Therapeutics 9 (6) , pp. 1574-1582. 10.1158/1535-7163.MCT-10-0104

Burnett, Alan Kenneth, Hills, Robert Kerrin, Green, Claire, Jenkinson, Sarah, Koo, Kenneth, Patel, Yashma, Guy, Carol, Gilkes, Amanda F., Milligan, Donald W., Goldstone, Anthony. H., Prentice, Archibald G., Wheatley, Keith, Linch, David C. and Gale, Rosemary E. 2010. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 115 (5) , pp. 948-956. 10.1182/blood-2009-08-236588

Burnett, Alan Kenneth, Russell, N. H., Kell, J., Dennis, M., Milligan, D., Paolini, S., Yin, J., Culligan, D., Johnston, P., Murphy, J., McMullin, M. F., Hunter, A., Das-Gupta, E., Clark, R., Carr, R. and Hills, R. K. 2010. European Development of Clofarabine as Treatment for Older Patients With Acute Myeloid Leukemia Considered Unsuitable for Intensive Chemotherapy. Journal of Clinical Oncology 28 (14) , pp. 2389-2395. 10.1200/JCO.2009.26.4242

Green, C. L., Evans, C. M., Hills, Robert Kerrin, Burnett, Alan Kenneth, Linch, D. C. and Gale, R. E. 2010. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukaemia is dependent on FLT3/ITD status [Abstract]. British Journal of Haematology 149 (S1) , p. 17. 10.1111/j.1365-2141.2010.08116.x

Dohner, Hartmut, Estey, Elihu H., Amadori, Sergio, Appelbaum, Frederick R., Buchner, Thomas, Burnett, Alan Kenneth, Dombret, Herve, Fenaux, Pierre, Grimwade, David, Larson, Richard A., Lo-Coco, Francesco, Naoe, Tomoki, Niederwieser, Dietger, Ossenkoppele, Gert J., Sanz, Miguel A., Sierra, Jorge, Tallman, Martin S., Lowenberg, Bob and Bloomfield, Clara D. 2010. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115 (3) , pp. 453-474. 10.1182/blood-2009-07-235358

Green, Claire L., Evans, Catherine M., Hills, Robert Kerrin, Burnett, Alan Kenneth, Linch, David C. and Gale, Rosemary E. 2010. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116 (15) , pp. 2779-2782. 10.1182/blood-2010-02-270926

Harrison, Chirstine J., Hills, Robert Kerrin, Moorman, Anthony V., Grimwade, David J., Hann, Ian, Webb, David K. H., Wheatley, Keith, de Graaf, Siebold S. N., van den Berg, Eva, Burnett, Alan Kenneth and Gibson, Brenda E. S. 2010. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12. Journal of Clinical Oncology 28 (16) , pp. 2674-2681. 10.1200/JCO.2009.24.8997

Green, Claire, Koo, K. K., Hills, Robert Kerrin, Burnett, Alan Kenneth, Linch, D. C. and Gale, R. E. 2010. Prognostic Significance of CEBPA Mutations in a Large Cohort of Younger Adult Patients With Acute Myeloid Leukemia: Impact of Double CEBPA Mutations and the Interaction With FLT3 and NPM1 Mutations. Journal of Clinical Oncology 28 (16) , pp. 2739-2747. 10.1200/JCO.2009.26.2501

Löwenberg, Bob, Morgan, Gareth, Ossenkoppele, Gert J., Burnett, Alan Kenneth, Zachee, Pierre, Dührsen, Ulrich, Dierickx, Daan, Muller-Tidow, Carsten, Sonneveld, Pieter, Krug, Utz, Bone, Elizabeth, Flores, Nicholas, Richardson, Alison F., Hooftman, Leon, Jenkins, Chris, Zweegman, Sonja and Davies, Faith 2010. Phase I/II clinical study of tosedostat, an Inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. Journal of Clinical Oncology 28 (28) , pp. 4333-4338. 10.1200/JCO.2009.27.6295

Knapper, Steven, Burnett, Alan Kenneth, Hills, Robert Kerrin, Small, Donald and Levis, Mark 2009. Lestaurtinib FLT3 inhibitory activity is modulated by concomitant azole therapy and may Influence relapse risk. Blood -New York- 114 (22) , p. 326.

Burnett, Alan Kenneth, Hills, Robert Kerrin, Milligan, Donald, Hunter, Ann E., Goldstone, Anthony H., Prentice, Archie G., Gibson, Brenda E. S., Kjeldsen, Lars, Yin, John A. L., Wheatley, Keith and Russell, Nigel H. 2009. Attempts to optimise induction and consolidation chemotherapy in patients with Acute Myeloid Leukaemia: results of the MRC AML15 trial. Blood -New York- 114 (22) , p. 200.

Russell, Nigel H., Howman, Andrew J., Wheatley, Keith, Hills, Robert Kerrin, Craddock, Charles, Kjeldsen, Lars, Yin, John A. L. and Burnett, Alan Kenneth 2009. Outcome of reduced intensity allografts in patients aged over 45 years with Acute Myeloid Leukaemia: initial results of the MRC AML15 trial. Blood -New York- 114 (22) , p. 217.

Russell, N. H., Hills, Robert Kerrin, Hunter, A. E., Milligan, D., Kell, W. J., Wheatley, K., McMullin, M. F., Yin, J. A. L., Bowen, D. T. and Burnett, Alan Kenneth 2009. Low dose Ara-C versus low dose Ara-C and arsenic trioxide: The UK NCRI AML16 "Pick a Winner" comparison [Abstract]. Blood 114 (22) , p. 201.

Grimwade, David, Jovanovic, Jelena V., Hills, Robert Kerrin, Nugent, Elizabeth A., Patel, Yashma, Flora, Rajinder, Diverio, Daniela, Jones, Katy, Aslett, Hannah, Batson, Elaine, Rennie, Kristian, Angell, Roger, Clark, Richard E., Solomon, Ellen, Lo-Coco, Francesca, Wheatley, Keith and Burnett, Alan Kenneth 2009. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. Journal of Clinical Oncology 27 (22) , pp. 3650-3658. 10.1200/JCO.2008.20.1533

McLornan, P., McMullin, M. F., Mills, Kenneth Ian, Hills, Robert Kerrin, Gilkes, Amanda F., Burnett, Alan Kenneth, Johnston, P. and Longley, D. B. 2009. The prognostic role of C-Flip in AML [Abstract]. Haematologica 94 (S2) , p. 108.

Burnett, Alan Kenneth, Milligan, D., Goldstone, A., Prentice, A., McMullin, M. F., Dennis, M., Sellwood, E., Pallis, M, Russell, N., Hills, Robert Kerrin and Wheatley, K. 2009. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British Journal of Haematology 145 (3) , pp. 318-332. 10.1111/j.1365-2141.2009.07604.x

Wheatley, Keith, Goldstone, Anthony H., Littlewood, Tim, Hunter, Anne and Burnett, Alan Kenneth 2009. Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. British Journal of Haematology 146 (1) , pp. 54-63. 10.1111/j.1365-2141.2009.07710.x

Harousseau, Jean-Luc, Martinelli, Giovanni, Jedrzejczak, Wieslaw W., Brandwein, Joseph M., Bordessoule, Dominique, Masszi, Tamas, Ossenkoppele, Gert J., Alexeeva, Julia A., Beutel, Gernot, Maertens, Johan, Vidriales, Maria-Belen, Dombret, Herve, Thomas, Xavier, Burnett, Alan Kenneth, Robak, Tadeusz, Khuageva, Nuriet K., Golenkov, Anatoly K., Tothova, Elena, Mollgard, Lars, Park, Youn C., Bessems, Annick, De Porre, Peter and Howes, Angela J. 2009. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 114 (6) , pp. 1166-1173. 10.1182/blood-2009-01-198093

Grimwade, D., Jovanovic, J. V., Hills, Robert Kerrin, Solomon, E., Lo-Coco, F., Wheatley, K. and Burnett, Alan Kenneth 2009. Reply to S. Nagai et al [Letter]. Journal of Clinical Oncology 28 (4) , e63-e64. 10.1200/JCO.2009.25.0522

Magar, R. S., Purdy, C., Hayward, A., Einarson, T. R. and Burnett, Alan Kenneth 2009. PCN83 Cost-effectiveness analysis of histamine dihydrochloride + low dose interleukin-2 vs standard of care for acute myeloid leukemia patients in their first complete remission: a UK perspective [Abstract]. Value in Health 12 (7) , A272. 10.1111/j.1524-4733.2009.00592_2.x

Advani, Anjali S., Hunger, Stephen P. and Burnett, Alan Kenneth 2009. Acute Leukemia in Adolescents and Young Adults. Seminars in Oncology 36 (3) , pp. 213-226. 10.1053/j.seminoncol.2009.03.007

Burnett, Alan Kenneth and Knapper, Steven 2009. Acute myeloid leukaemia. In: Treleaven, Jennifer G. and Barrett, A. John eds. Hematopoietic Stem Cell Transplantation in Clinical Practice, Edinburgh: Churchill Livingstone Elsevier, pp. 25-34.

Burnett, Alan Kenneth, Milligan, Donald, Goldstone, Anthony, Prentice, Archibald, McMullin, Mary-Frances, Dennis, Michael, Sellwood, Elizabeth, Pallis, Monica, Russell, Nigel, Hills, Robert K. and Wheatley, Keith 2009. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British Journal of Haematology 145 (3) , pp. 318-332. 10.1111/j.1365-2141.2009.07604.x

Wheatley, Keith, Brookes, Cassandra l., Howman, Andrew J., Goldstone, Anthony H., Milligan, Donald W., Prentice, Archibald G., Moorman, Anthony V. and Burnett, Alan Kenneth 2009. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. British Journal of Haematology 145 (5) , pp. 598-605. 10.1111/j.1365-2141.2009.07663.x

Sanz, Miguel A., Grimwade, David, Tallman, Martin S., Lowenberg, Bob, Fenaux, Pierre, Estey, Elihu H., Naoe, Tomoki, Lengfelder, Eva, Buchner, Thomas, Dohner, Hartmut, Burnett, Alan Kenneth and Lo-Coco, Francesco 2009. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113 (9) , pp. 1875-1891. 10.1182/blood-2008-04-150250

Fitzgibbon, J., Gale, R., Hills, Robert Kerrin, Virappane, P., Burnett, Alan Kenneth, Lister, T. A. and Linch, D. 2009. In Reply [to 'Comparing Apples and Oranges in Normal Karyotype Acute Myeloid Leukemia' by Bruno C. Medeiros] [Letter]. Journal of Clinical Oncology 27 (3) , pp. 474-476. 10.1200/JCO.2008.19.4894

Hewamana, Saman, Lin, Thet Thet, Jenkins, Chris, Burnett, Alan Kenneth, Jordan, Craig T., Fegan, Christopher Daniel, Brennan, Paul, Rowntree, Clare and Pepper, Christopher John 2008. The novel nuclear factor- B inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clinical Cancer Research 14 (24) , pp. 8102-8111. 10.1158/1078-0432.CCR-08-1673

Gale, Rosemary, Hills, Robert Kerrin, Green, Claire, Patel, Yashma, Gilkes, Amanda F., Lazenby, Michelle, Wheatley, Keith, Linch, David C. and Burnett, Alan Kenneth 2008. The impact of FLT3-ITD and NPM1 Mutational Status on the outcome of ATRA therapy in patients with Non-APL AML: results of the UK MRC AML12 trial [Abstract]. Blood -New York- 112 (11) , p. 207.

Liu-Yin, John A., Sale, M., Daly, Sarah B., Hills, Robert Kerrin, Wheatley, Keith and Burnett, Alan Kenneth 2008. Predictive value of Minimal Residual Disease (MRD) monitoring by RQ-PCR in WT1 positive patients entered in the UK MRC AML-15 trial. Blood -New York- 112 (11) , pp. 259-260.

Mansour, M. R., Gale, R., Khwaja, A., Pule, M, Hills, Robert Kerrin, Burnett, Alan Kenneth and Linch, D. 2008. CSL-TREX: A novel alternatively spliced isoform of CSL (RBPJ-K) predominates over the full-length isoform in many patients with acute myeloid leukaemia can activate notch signalling and is associated with improved outcome [Abstract]. Blood 112 (11) , p. 1155.

Virappane, P., Gale, R., Hills, Robert Kerrin, Kakkas, I., Summers, K., Stevens, J., Allen, C., Green, C., Quentmeier, H., Drexler, H., Burnett, Alan Kenneth, Linch, D., Bonnet, D., Lister, T. A. and Fitzgibbon, J. 2008. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology 26 (33) , pp. 5429-5435. 10.1200/JCO.2008.16.0333

Burnett, Alan Kenneth, Hills, Robert Kerrin, Milligan, Donald, Kell, William J., Wheatley, Keith, Virchis, Andres E. and Russell, Nigel H. 2008. Low dose Ara-C versus low Dose Ara-C and Tipifarnib: result of the UK NCRI AML16 "Pick a Winner" comparison [Abstract]. Blood -New York- 112 (11) , pp. 1017-1018.

Hills, Robert Kerrin, O'Brien, S., Karsten, V., Burnett, Alan Kenneth and Giles, F. 2008. A retrospective comparison of matched elderly patients treated with Laromustine (Cloretazine (R)) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial [Abstract]. Blood 112 (11) , p. 1017.

Hewamana, Saman, Alghazal, Suhair Alkailani, Lin, Thet Thet, Clement, Matthew, Jenkins, Christopher, Guzman, Monica L., Jordan, Craig T., Neelakantan, Sundar, Crooks, Peter A., Burnett, Alan Kenneth, Pratt, Guy, Fegan, Christopher Daniel, Rowntree, Clare, Brennan, Paul and Pepper, Christopher John 2008. The NF-κB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111 (9) , pp. 4681-4689. 10.1182/blood-2007-11-125278

Grimwade, D., Jovanovic, J. V., Hills, Robert Kerrin, Nugent, E. A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., Clark, R. E., Solomon, E., Lo Coco, F., Wheatley, K. and Burnett, Alan Kenneth 2008. Evaluation of prospective real-time quantitative PCR monitoring for minimal residual disease to predict relapse and direct molecularly targeted therapy with arsenic trioxide in acute promyelocytic leukaemia: analysis of 407 patients, including results of the MRC AML15 trial [Abstract]. British Journal of Haematology 141 (S1) , p. 59.

Burnett, Alan Kenneth 2008. Antibody targeted chemotherapy in AML-MRC experience. Annals of Hematology 87 (S1) , S94-S94.

Al Shaer, Laila, Walsby, Elisabeth Jane, Gilkes, Amanda F., Tonks, Amanda Jayne, Walsh, Valerie, Mills, Kenneth Ian, Burnett, Alan Kenneth and Rowntree, Clare 2008. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. British Journal of Haematology 141 (4) , pp. 483-493. 10.1111/j.1365-2141.2008.07053.x

Walsby, Elisabeth Jane, Walsh, Val, Pepper, Christopher John, Burnett, Alan Kenneth and Mills, Ken 2008. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 93 (5) , pp. 662-669. 10.3324/haematol.12148

Owen, Carolyn, Virappane, Priya, Alikian, Mary, Stasevich, Irina, Summers, Karin, Lillington, Debbie, Bonnet, Dominique, Burnett, Alan Kenneth, Mills, Ken, Lister, T. Andrew and Fitzgibbon, Jude 2008. WTX is rarely mutated in acute myeloid leukemia. Haematologica 93 (6) , pp. 947-948. 10.3324/haematol.12509

Guy, Carol, Gilkes, Amanda F., Gale, Rosemary, Linch, David C., Hills, Robert Kerrin and Burnett, Alan Kenneth 2008. The impact of MN1 over-expression on the outcome of younger patients with AML treated with intensive chemotherapy with or without ATRA therapy [Abstract]. Blood -New York- 112 (11) , p. 1023.

Jenkins, Christopher, Hewamana, Saman, Gilkes, Amanda F., Neelakantan, Sundar, Crooks, Peter, Mills, Ken, Pepper, Christopher John and Burnett, Alan Kenneth 2008. Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. British Journal of Haematology 143 (5) , pp. 661-671. 10.1111/j.1365-2141.2008.07392.x

Bowen, D., Groves, M. J., Burnett, Alan Kenneth, Patel, Y., Allen, C., Green, C., Gale, R. E., Hills, Robert Kerrin and Linch, D. C. 2008. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis [Letter]. Leukemia 23 (1) , pp. 203-206. 10.1038/leu.2008.173

Gale, Rosemary E., Green, Claire, Allen, Christopher, Mead, Adam J., Burnett, Alan Kenneth, Hills, Robert Kerrin and Linch, David C. 2008. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111 (5) , pp. 2776-2784. 10.1182/blood-2007-08-109090

Goldstone, Anthony H., Richards, Susan M., Lazarus, Hilliard M., Tallman, Martin S., Buck, Georgina, Fielding, Adele K., Burnett, Alan Kenneth, Chopra, Raj, Wiernik, Peter H., Foroni, Letizia, Paietta, Elizabeth, Litzow, Mark R., Marks, David I., Durrant, Jill, McMillan, Andrew, Franklin, Ian M., Luger, Selina, Ciobanu, Niculae and Rowe, Jacob M. 2008. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111 (4) , pp. 1827-1833. 10.1182/blood-2007-10-116582

Mead, Adam J., Gale, Rosemary E., Hills, Robert Kerrin, Gupta, Manu, Young, Bryan D., Burnett, Alan Kenneth and Linch, David C. 2008. Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease [Letter]. Blood 112 (2) , pp. 444-445. 10.1182/blood-2008-02-140392

Tonks, Alex, Pearn, Lorna, Musson, Megan, Gilkes, Amanda F., Mills, Kenneth Ian, Burnett, Alan Kenneth and Darley, Richard Lawrence 2007. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 21 (12) , pp. 2495-2505. 10.1038/sj.leu.2404961

Ravandi, Farhad, Burnett, Alan Kenneth, Agura, Edward D. and Kantarjian, Hagop M. 2007. Progress in the treatment of acute myeloid leukemia. Cancer 110 (9) , pp. 1900-1910. 10.1002/cncr.23000

Burnett, Alan Kenneth, Hills, Robert Kerrin, Grimwade, David, Goldstone, Anthony H., Hunter, Ann, Milligan, Donald, Prentice, Archie G., Russell, Nigel H. and Wheatley, Keith 2007. Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukaemia with lower toxicity and resource usage: Preliminary results of the MRC AML15 trial. Blood -New York- 110 (11) , 181A-181A.

Yin, J. A. L., Daly, S. B., Sale, M. A., Green, S., Tobal, K., Hills, Robert Kerrin and Burnett, Alan Kenneth 2007. Minimal residual disease monitoring by RQ-PCR in core binding factor positive AML allows risk-stratification and predicts relapse: Results of the UK MRC AML-15 trial. Blood 110 (11) , 167A.

Burnett, Alan Kenneth and Kell, J. 2007. Tipifarnib in acute myeloid leukemia. Drugs of Today 43 (11) , pp. 795-800. 10.1358/dot.2007.43.11.1088617

Mead, Adam J., Linch, David C., Hills, Robert Kerrin, Wheatley, Keith, Burnett, Alan Kenneth and Gale, Rosemary E. 2007. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110 (4) , pp. 1262-1270. 10.1182/blood-2006-04-015826

Virappane, P., Gale, R. E., Hills, Robert Kerrin, Kakkas, K., Summers, K., Stevens, J., Green, C. L., Allen, C. G., Quentmeier, H., Drexler, H., Burnett, Alan Kenneth, Linch, D. .C, Bonnet, D., Listens, T. A. and Fitzgibbon, J. 2007. Wilms' tumour 1 mutation in normal karyotype aml. Haematologica 92 (S1) , pp. 19-20.

van den Heuvel-Eibrink, M. M., van der Holt, B., Burnett, Alan Kenneth, Knauf, W. U., Fey, M. F., Verhoef, G. E., Vellenga, E., Ossenkoppele, G. J., Lowenberg, B. and Sonneveld, P. 2007. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Annals of Hematology 86 (5) , pp. 329-337. 10.1007/s00277-007-0269-7

Grimwade, D., Jovanovic, J. .V, Diverio, D., Nugent, E., Ho, A. Y., Mufti, G. J., Harrison, P., Neilson, J., Solomon, E., Hills, Robert Kerrin, Clark, R. E., Lo Coco, F. and Burnett, Alan Kerrin 2007. Use of quantitative PCR approaches to predict relapse and direct molecularly targeted therapy with arsenic trioxide (ATO) in acute promyelocytic leukaemia (APL)[Abstract]. British Journal of Haematology 137 (S1) , p. 39. 10.1111/j.1365-2141.2007.06557.x

Burnett, Alan Kenneth, Milligan, Donald, Prentice, Archie G., Goldstone, Anthony H., McMullin, Mary F., Hills, Robert Kerrin and Wheatley, Keith 2007. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109 (6) , pp. 1114-1124. 10.1002/cncr.22496

Tonks, Alex, Hills, Robert Kerrin, White, Paul Charles, Rosie, B., Mills, Kenneth Ian, Burnett, Alan Kenneth and Darley, Richard Lawrence 2007. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21 (3) , pp. 566-568. 10.1038/sj.leu.2404559

Tonks, Alex, Hills, Robert Kerrin, White, Paul Charles, Rosie, B., Mills, Kenneth Ian, Burnett, Alan Kenneth and Darley, Richard Lawrence 2007. CD200 as a prognostic factor in acute myeloid leukaemia [Letter]. Leukemia 21 (3) , pp. 566-568. 10.1038/sj.leu.2404559

Pearn, Lorna, Fisher, Janet, Burnett, Alan Kenneth and Darley, Richard Lawrence 2007. The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood 109 (10) , pp. 4461-9. 10.1182/blood-2006-09-047217

Burnett, Alan Kenneth and Knapper, Steven 2007. Targeting treatment in AML. Hematology: American Society of Haematology Education Program Book 2007 (1) , pp. 429-434. 10.1182/asheducation-2007.1.429

van der Holt, Bronno, Breems, Dimitri A., Berna Beverloo, H., van den Berg, Eva, Burnett, Alan Kenneth, Sonneveld, Pieter and Löwenberg, Bob 2007. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. British Journal of Haematology 136 (1) , pp. 96-105. 10.1111/j.1365-2141.2006.06403.x

Mohite, U., Kell, J., Haj, M. A., O'Brien, C., Kundu, S., Rees, J. and Burnett, Alan Kenneth 2007. Invasive aspergillosis localised to the colon presenting as toxic megacolon. European Journal of Haematology 78 (3) , pp. 270-273. 10.1111/j.1600-0609.2006.00812.x

Seedhouse, C. H., Grundy, M., White, Paul Charles, Li, Y., Fisher, Janet, Yakunina, Darya, Moorman, A. V., Hoy, Terence, Russell, N., Burnett, Alan Kenneth and Pallis, M. 2007. Sequential Influences of Leukemia-Specific and Genetic Factors on P-glycoprotein expression in blasts from 817 patients entered into the national cancer research network acute myeloid leukemia 14 and 15 trials. Clinical Cancer Research 13 (23) , pp. 7059-7066. 10.1158/1078-0432.CCR-07-1484

Burnett, Alan Kenneth 2007. MRC trials in acute myeloblastic luekemia: Where have we got to? Leukemia & Lymphoma 48 (12) , pp. 2289-2290. 10.1080/10428190701706139

Wheatley, K., Hills, Robert Kerrin and Burnett, Alan Kenneth 2006. Problems with up-front randomization in clinical trials. Journal of Clinical Oncology 24 (34) , pp. 5471-5472. 10.1200/JCO.2006.08.3048

Knapper, Steven, Mills, Kenneth I., Gilkes, Amanda F., Austin, Steve J., Walsh, Valerie and Burnett, Alan K. 2006. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 108 (10) , pp. 3494-3503. 10.1182/blood-2006-04-015487

Knapper, Steven, Burnett, Alan K., Littlewood, Tim, Kell, William Jonathan, Agrawal, Sam, Chopra, Raj, Clark, Richard, Levis, Mark J. and Small, Donald 2006. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108 (10) , pp. 3262-3270. 10.1182/blood-2006-04-015560

Hills, Robert Kerrin, Kell, W. J. and Burnett, Alan Kenneth 2006. Treatment of AML in the elderly: Who is "Fit" for intensive chemotherapy? Blood -New York- 108 (11) , 559A-559A.

Burnett, Alan Kenneth, Kell, William J., Hills, Robert Kerrin, Russe, Nigel H., Yin, John, Hunter, Ann and Culligan, Dominic 2006. The feasibility of combining daunorubicin, clofarabine and gemtuzumab ozogamicin ts feasible and effective. A pilot study. Blood -New York- 108 (11) , 551A-552A.

Burnett, Alan Kenneth, Baccarani, M., Johnson, Peter, Yin, John, Sounders, Andrew, Russell, Nigel and Hills, Robert Kerrin 2006. A phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable. Blood -New York- 108 (11) , 130A-130A.

Burnett, Alan Kenneth, Hills, Robert K., Wheatley, Keith, Goldstone, Anthony H., Prentice, Archie G. and Milligan, Donald 2006. A sensitive risk score for directing treatment in younger patients with AML. Blood -New York- 108 (11) , 10A-10A.

Burnett, Alan Kenneth, Kell, William J., Goldstone, Anthony H., Milligan, Donald, Hunter, Ann, Prentice, Archie G., Russell, Nigel H., Gibson, Brenda, Wheatley, Keith and Hills, Robert Kerrin 2006. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial. Blood -New York- 108 (11) , 8A-8A.

Guinn, Barbara-ann, Gilkes, Amanda F., Mufti, Ghulam J., Burnett, Alan Kenneth and Mills, Kenneth Ian 2006. The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia. British Journal of Haematology 134 (2) , pp. 238-239. 10.1111/j.1365-2141.2006.06135.x

Hillard, M. L., Richards, S. M., Chopra, R., Litzow, M. R., Burnett, Alan Kenneth, Wiernik, P. H., Franklin, I. M., Tallman, M. S., Cook, L., Buck, G., Durrant, I. J., Rowe, J. M. and Goldstone, A. H. 2006. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood -New York- 108 (2) , pp. 465-472. 10.1182/blood-2005-11-4666

Milligan, Donald W., Wheatley, Keith, Littlewood, Timothy, Craig, Jenny I. O. and Burnett, Alan Kenneth 2006. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 107 (12) , pp. 4614-22. 10.1182/blood-2005-10-4202

Burnett, Alan Kenneth, Wheatley, K., Goldstone, A. H., Stevens, R., Hann, I. and Hills, R. K. 2006. Long-term results of the MRC AML10 trial. Clinical Advances in Hematology and Oncology 4 (6) , pp. 445-451.

Jordanides, N. E., Keith, W. N., Hills, Robert Kerrin, Wheatley, Keith, Luong, Quang T., Burnett, Alan Kenneth, Holyoake, T. L. and Drummond, M. W. 2006. hTERT expression in AML is heterogeneous and is of likely prognostic significance. British Journal of Haematology 133 (S1) , p. 63. 10.1111/j.1365-2141.2006.06027.x

Burnett, Alan Kenneth and Mohite, Unmesh 2006. Treatment of older patients with acute myeloid leukemia-new agents. Seminars in Hematology 43 (2) , pp. 96-106. 10.1053/j.seminhematol.2006.01.003

Burnett, Alan Kenneth 2006. The challenge of the older patient [Abstract]. Annals of Hematology 85 (1 Supp) , pp. 60-61. 10.1007/s00277-005-0079-8

Dasgupta, R. K., Rule, S., Johnson, P., Davies, J., Burnett, Alan Kenneth, Poynton, Christopher, Wilson, Keith, Smith, G. M., Jackson, G., Richardson, C., Wareham, E., Stars, A. C., Tollerfield, S. M. and Morgan, G. J. 2006. Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone Marrow Transplantation -Basingstoke then London- 37 (5) , pp. 455-461. 10.1038/sj.bmt.1705271

Goodwin, Richard G., Kell, William Jonathan, Laidler, Peter, Long, C. Colin, Whatley, Sharon D., McKinley, Mark, Badminton, Michael Norman, Burnett, Alan Kenneth, Williams, Geraint Trefor and Elder, George Hill 2006. Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelastase gene in hematopoietic cells. Blood 107 (1) , pp. 60-62. 10.1182/blood-2004-12-4939

Omidvar, Nader, Pearn, Lorna, Burnett, Alan Kenneth and Darley, Richard Lawrence 2006. Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by Ras. Molecular and cellular biology 26 (10) , pp. 3966-75. 10.1128/MCB.26.10.3966-3975.2006
file

Tonks, Alex, Pearn, Lorna, Mills, Kenneth Ian, Burnett, Alan Kenneth and Darley, Richard Lawrence 2006. The sensitivity of human cells expressing RUNX1-RUNX1T1 to chemotherapeutic agents. Leukemia 20 (10) , pp. 1883-5. 10.1038/sj.leu.2404364

Goodwin, Richard G., Kell, W. Jonathan, Laidler, Peter, Long, Colin C., Whatley, Sharon D., McKinley, Mark, Badminton, Michael Norman, Burnett, Alan Kenneth, Williams, Geraint Trefor and Elder, George H. 2006. Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells. Blood 107 (1) , pp. 60-62. 10.1182/blood-2004-12-4939

Rowe, Jacob M., Buck, Georgina, Burnett, Alan Kenneth, Chopra, Raj, Wiernik, Peter H., Richards, Susan M., Lazarus, Hillard M., Franklin, Ian M., Litzow, Mark R., Ciobanu, Niculae, Prentice, H. Grant, Durrant, Jill, Tallman, Martin S. and Goldstone, Anthony H. 2005. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 106 (12) , pp. 3760-3767. 10.1182/blood-2005-04-1623

Wheatley, K., Brookes, C. L, Hills, Robert Kerrin, Goldstone, A. H., Milligan, D. W., Prentice, A. G., Moorman, A. V. and Burnett, Alan Kenneth 2005. Prognostic factors in older AML patients receiving intensive and non-intensive therapy: Analysis of the UK AML11 and AML14 trials [Abstract]. Blood 106 (11) , 199A.

Mead, Adam, Linch, David, Hills, Robert Kerrin, Wheatley, Keith, Burnett, Alan Kenneth and Gale, Rosemary 2005. Favourable prognosis associated with FLT3 tyrosine kinase domain mutations in AML in contrast to the adverse outcome associated with internal tandem duplications [Abstract]. Blood 106 (11) , 334.

Gale, Rosemary E., Hills, Robert Kerrin, Kottaridis, Panagiotis D., Srirangan, Sivatharsini, Wheatley, Keith, Burnett, Alan Kenneth and Linch, David C. 2005. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 106 (10) , pp. 3658-65. 10.1182/blood-2005-03-1323

Bowen, David T., Frew, Marion E., Hills, Robert Kerrin, Gale, Rosemary E., Wheatley, Keith, Groves, Michael J., Langabeer, Stephen E., Kottaridis, Panagiotis D., Moorman, Anthony V., Burnett, Alan Kenneth and Linch, David C. 2005. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 106 (6) , pp. 2113-2119. 10.1182/blood-2005-03-0867

Guinn, Barbara-ann, Gilkes, Amanda F., Woodward, Eleanor, Westwood, Nigel B., Mufti, Ghulam J., Linch, David, Burnett, Alan Kenneth and Mills, Kenneth Ian 2005. Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia. Biochemical and Biophysical Research Communications 333 (3) , pp. 703-713. 10.1016/j.bbrc.2005.05.161

Peniket, A., Wainscoat, J., Side, L., Daly, S., Kusec, R., Buck, G., Wheatley, K., Walker, Helen, Chatters, S., Harrison, C., Boultwood, J., Goldstone, A. and Burnett, Alan Kenneth 2005. Del (9q) AML: clinical and cytological characteristics and prognostic implications. British Journal of Haematology 129 (2) , pp. 210-220. 10.1111/j.1365-2141.2005.05445.x

Tonks, Alex, Tonks, Amanda Jayne, Pearn, Lorna, Mohamad, Zulkhairi, Burnett, Alan Kenneth and Darley, Richard Lawrence 2005. Optimized retroviral transduction protocol which preserves the primitive subpopulation of human hematopoietic cells. Biotechnology Progress 21 (3) , pp. 953-958. 10.1021/bp0500314

Gale, Rosmary E., Hills, Robert Kerrin, Pizzey, Arnold R., Kottaridis, Panagiotis D., Swirsky, David, Gilkes, Amanda F., Nugent, Elizabeth, Mills, Kenneth I., Wheatley, Keith, Solomon, Ellen, Burnett, Alan Kenneth, Linch, David C. and Grimwade, David 2005. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106 (12) , pp. 3768-3776. 10.1182/blood-2005-04-1746

Burnett, Alan Kenneth, Hills, Robert Kerrin, Goldstone, A. H., Milligan, D., Prentice, A. G., Hann, I., Webb, D., Gibson, B. and Wheatley, K. 2004. The impact of transplant in AML in 2nd CR: A prospective study of 741 in the MRC AML 10 and 12 Trials [Abstract]. Blood 104 (11) , 179A.

Burnett, Alan Kenneth, Milligan, Donald, Hills, Robert Kerrin, Goldstone, Anthony H., Prentice, Archie G., Wheatley, Keith, Webb, David C. and Gibson, Brenda 2004. Does all-transretinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia?: Results from 1666 patients in three MRC trials [Abstract]. Blood 104 (11) , 1794.

Milligan, D., Wheatley, K. and Burnett, Alan Kenneth 2004. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. British Journal of Haematology 127 (2) , pp. 238-239. 10.1111/j.1365-2141.2004.05185.x

Tonks, Alex, Tonks, Amanda Jayne, Pearn, Lorna, Pearce, Laurence, Hoy, Terence George, Couzens, Stephen, Fisher, Janet, Burnett, Alan Kenneth and Darley, Richard Lawrence 2004. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 18 (7) , pp. 1238-1245. 10.1038/sj.leu.2403396

Tonks, Alex, Tonks, Amanda Jayne, Pearn, Lorna, Pearce, L., Hoy, T., Couzens, Stephen, Fisher, J., Burnett, Alan Kenneth and Darley, Richard Lawrence 2004. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 18 (7) , pp. 1238-1245. 10.1038/sj.leu.2403396

Watson, M., Buck, G., Wheatley, K., Homewood, J. R., Goldstone, A. H., Rees, J. K. H. and Burnett, Alan Kenneth 2004. Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients. European Journal of Cancer 40 (7) , pp. 971-978. 10.1016/S0959-8049(03)00628-2

Tennant, Graham Burt, Cavill, Ivor and Burnett, Alan Kenneth 2004. Long-term survival of myelodysplastic patients with macrocytosis. British Journal of Haematology 124 (6) , pp. 840-841. 10.1111/j.1365-2141.2004.04860.x

Kell, William Jonathan, Burnett, Alan Kenneth, Chopra, Raj, Yin, John A. L., Clark, Richard E., Rohatiner, Ama, Culligan, Dominic, Hunter, Ann, Prentice, Archie G. and Milligan, Donald W. 2003. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102 (13) , pp. 4277-83. 10.1182/blood-2003-05-1620

Burnett, Alan Kenneth, Hills, Robert Kerrin and Wheatley, Keith 2003. Does centre size influence outcome in the treatment of AML in adult patients under 60 years? The MRC AML trial experience [Abstract]. Blood 102 (11) , 616A-617A.

Burnett, Alan Kenneth, Hills, Robert Kerrin, Goldstone, A. H., Prentice, A., Milligan, D., Pallis, M., Russell, N., Truran, L. N. and Wheatley, K. 2003. Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of the LRF AML14 trial. Blood 102 (11) , 614A.

Luong, Quang T., Hills, Robert Kerrin, Drayson, Mark T., Wheatley, Keith, Burnett, Alan Kenneth, Linch, David C. and Bunce, Christopher M. 2003. Expression of Nm23-H1 in AML correlates with white cell count at diagnosis and in vitro acts as a survival factor for primary AMLs cells; evidence of a novel autocrine survival factor in AML. Blood -New York- 102 (11) , 611A-611A.

Tonks, Alex, Pearn, Lorna, Tonks, Amanda Jayne, Pearce, Laurence, Hoy, Terence George, Phillips, Sarah, Fisher, Janet, Downing, James R., Burnett, Alan Kenneth and Darley, Richard Lawrence 2003. The AML-1 fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 101 (2) , pp. 624-632. 10.1182/blood-2002-06-1732

Tonks, Alex, Pearn, Lorna, Tonks, Amanda Jayne, Pearce, Laurence, Hoy, Terence George, Phillips, Sarah, Fisher, Janet, Downing, James R., Burnett, Alan Kenneth and Darley, Richard Lawrence 2003. The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 101 (2) , pp. 624-632. 10.1182/blood-2002-06-1732

Darley, Richard Lawrence, Pearn, Lorna, Omidvar, Nader, Sweeney, Marion Carol, Fisher, Janet, Phillips, Sarah, Hoy, Terence George and Burnett, Alan Kenneth 2002. Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in normal human erythroid cells. Blood 100 (12) , pp. 4185-92. 10.1182/blood-2002-05-1358

Baines, Paul, Austin, Steve, Fisher, Janet, Owen-Jones, Catrin Eleri, Lee-Jones, Lisa, Throp, Duncan, Mckinley, Mark, Hoy, Terry, Mills, Ken, Thompson, Peter W. and Burnett, Alan Kenneth 2002. Increased circulating normal and BCR-ABL+Ve progenitor numbers in Philadelphia chromosome-positive acute myeloid leukaemia. Leukemia Research 26 (11) , pp. 997-1005. 10.1016/S0145-2126(02)00049-8

Tennant, Graham Burt, Al-Sabah, Ala I and Burnett, Alan Kenneth 2002. Prognosis of myelodysplasic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number. British Journal of Haematology 119 (1) , pp. 87-96. 10.1046/j.1365-2141.2002.03783.x

Burnett, Alan Kenneth 2002. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an adult treater's view [review]. British Journal of Haematology 118 (2) , pp. 357-364. 10.1046/j.1365-2141.2002.03698.x

Burnett, Alan Kenneth, Wheatley, Keith, Goldstone, Anthony H., Stevens, Richard F., Hann, Ian M., Rees, John H. K. and Harrison, Georgina 2002. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. British Journal of Haematology 118 (2) , pp. 385-400. 10.1046/j.1365-2141.2002.03724.x

Gharib, M. I. and Burnett, Alan Kenneth 2002. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis [Review]. European Journal of Heart Failure 4 (3) , pp. 235-242. 10.1016/s1388-9842(01)00201-x

Burnett, Alan Kenneth 2002. Acute myeloid leukemia: treatment of adults under 60 years [Review]. Reviews in Clinical and Experimental Hematology 6 (1) , pp. 26-45. 10.1046/j.1468-0734.2002.00058.x

Dorak, M. Trevfik, Lawson, T., Machulla, H. K. G., Mills, Kenneth Ian and Burnett, Alan Kenneth 2002. Increased heterozygosity for MHC class II lineages in newborn males. Genes and Immunity 3 (5) , pp. 263-269. 10.1038/sj.gene.6363862

Truran, Louise N., Austin, Steve, Langabeer, S. J., Kottaridis, P. D., Linch, D. C., Fisher, J. and Burnett, Alan Kenneth 2001. Quantitative bax and FLT3-ITD characterisation improve prognostic stratification in AML patients with intermediate risk cytogenetics. Blood 98 (11) , 578A-578A.

Dorak, M. T., Machulla, H. K. G., Lawson, T., Mills, K. I. and Burnett, Alan Kenneth 2001. A female-specific susceptibility marker for childhood ALL in the TNF subregion of the HLA complex [Abstract]. Blood 98 (11) , 317A.

DeAngelo, D., Russo, D., Castaigne, S., Esteve, J., Burnett, Alan Kenneth, Goldstone, A., Tallman, M., Bradstock, K., Lowenberg, B., Leopold, L., Munteanu, M., Eten, C. and Berger, M. 2001. Preliminary report of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg (R)) given in combination with cytarabine and daunorubicin in patients with acute myeloid leukemia. Blood 98 (11) , 199B-199B.

Mills, K. I., Gilkes, A. F., Price, A. J., Walsh, V., Mason, L., Sweeney, M., Dann, E. and Burnett, Alan Kenneth 2001. The effect of HDAC inhibitors on gene expression in 32D cells expressing the AML1-ETO fusion gene. Blood 98 (11) , 566A-566A.

Mills, K. I., Walsh, V., Darley, R. L., Dann, E. and Burnett, Alan Kenneth 2001. The effect of histone deacetylase inhibitors on the growth and viability of myeloid cell lines. Blood 98 (11) , 119A-119A.

Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A., Walker, H., Wheatley, K., Bowen, D. T., Burnett, Alan Kenneth, Goldstone, A. H. and Linch, D. C. 2001. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98 (6) , pp. 1752-1759. 10.1182/blood.V98.6.1752

Goldstone, Anthony H., Burnett, Alan Kenneth, Wheatley, Keith, Smith, Alastair G., Hutchinson, R. Michael and Clark, Richard E. 2001. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98 (5) , pp. 1302-11. 10.1182/blood.V98.5.1302

Grimwade, David, Walker, Helen, Harrison, Georgina, Oliver, Fiona, Chatters, Stephen, Harrison, Christine J., Wheatley, Keith, Burnett, Alan Kenneth and Goldstone, Anthony H. 2001. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98 (5) , pp. 1312-1320. 10.1182/blood.V98.5.1312

Burnett, Alan Kenneth 2001. Introduction: Modern management of acute myeloid leukemia. Seminars in Hematology 38 (S 6) , pp. 1-2. 10.1016/S0037-1963(01)90149-0

Liu Yin, J. A., Wheatley, K, Rees, John K. H. and Burnett, Alan Kenneth 2001. Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. British Journal of Haematology 113 (3) , pp. 713-726. 10.1046/j.1365-2141.2001.02785.x

Burnett, Alan Kenneth 2001. Treatment of acute myeloid leukaemia in younger patients. Best Practice & Research Clinical Haematology 14 (1) , pp. 95-118. 10.1053/beha.2000.0118

Tennant, Graham B., Al-Sabah, Ala I. and Burnett, Alan Kenneth 2001. Simple two-way stratification of myelodysplastic patients as a basis for prognostic assessment. Blood 98 (11) , 276B-276B.

Langabeer, S. E., Rogers, J. R., Harrison, G., Wheatley, K., Walker, H., Bain, B. J., Burnett, Alan Kenneth, Goldstone, A. H., Linch, D. C. and Grimwade, D. 2001. EVI1 expression in acute myeloid leukaemia. British Journal of Haematology 112 , pp. 208-211. 10.1046/j.1365-2141.2001.02569.x

Burnett, Alan Kenneth 2001. Gemtuzumab ozogamicin - Viewpoint. Drugs 61 (9) , pp. 1323-1324. 10.2165/00003495-200161090-00009

Tennant, Graham Burt, Walsh, Valerie, Truran, L. N., Edwards, P., Mills, Kenneth Ian and Burnett, Alan Kenneth 2000. Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. British Journal of Haematology 111 (3) , pp. 853-862. 10.1111/j.1365-2141.2000.02467.x

Side, L. E., Peniket, A. J., Levy, E. R., Williamson, H., Humphray, S. J., Langabeer, S. E., Walker, H., Goldstone, A. H., Linch, D. C., Burnett, Alan, Boultwood, J and Wainscoat, J.S. 2000. Molecular characterization of the chromosome 9q deletion in AML [Abstract]. Blood 96 (11) , 542A.

Mills, K. I., Walsh, V., Darley, R. L., Gilkes, A. F., Dann, E. J. and Burnett, Alan Kenneth 2000. The histone deacetylase inhibitor trichostatin (TSA) induces neutrophil differentiation in 32D cells over-expressing AML1, but not in cells expressing either AML1-ETO or AML1-MDS genes. Blood 96 (11) , 122A-122A.

Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A., Walker, H., Wheatley, K., Bowen, D. T., Burnett, Alan Kenneth, Goldstone, A. H. and Linch, D. C. 2000. The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials. Blood 96 (11) , 825A-825A.

Davies, C. S., Walsh, V. A., Al-Sabah, A. I., Hoy, T., Burnett, Alan Kenneth and Mills, K. I. 2000. The treatment of 32D-BCR-ABL cells with 5-Aza-2 ' deoxycytidine prior to GM-CSF slows proliferation and induces differentiation. Blood 96 (11) , 352A-352A.

Davies, C. S., Plass, C., Smiraglia, D., Burnett, Alan Kenneth and Mills, K. I. 2000. The detection of regions of aberrant DNA methylation in chronic myeloid leukemia by restriction landmark genome scanning (RLGS). Blood 96 (11) , 350A-350A.

Burnett, Alan Kenneth, Kell, William Jonathan and Rowntree, Claire 2000. Acute myeloid leukemia: therapeutic indications [Review]. Current Opinion in Hematology 7 (6) , pp. 333-338. 10.1097/00062752-200011000-00002

Burnett, Alan, Kell, William Jonathan and Rowntree, Claire 2000. Role of allogeneic and autologous hematopoietic stem cell transplantation in acute myeloid leukemia. International Journal of Hematology 72 (3) , pp. 280-284.

Hofmann, W. K., Kell, W J., Fenaux, P., Castaigne, S., Ganser, A., Chomienne, C., Burnett, R., Kowal, C., Hoelzer, D. and Burnett, Alan Kenneth 2000. Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study. Leukemia 14 (9) , pp. 1583-1588. 10.1038/sj.leu.2401873

Tennant, G. B., Truran, L. N., Bailey-Wood, R. and Burnett, Alan Kenneth 2000. Control of pH in human long-term bone marrow cultures with low-glucose medium containing zwitterion buffer lengthens the period of haemopoietic activity. British Journal of Haematology 109 (4) , pp. 785-787. 10.1046/j.1365-2141.2000.02002.x

Iqbal, S., Grimwade, D., Chase, A., Goldstone, A., Burnett, Alan Kenneth, Goldman, J. M. and Swirsky, D. 2000. Identification of PML/RARα rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients. Leukemia 14 (5) , pp. 950-953. 10.1038/sj.leu.2401688

Guinn, B. A., Evely, R. S., Walsh, V., Gilkes, Amanda, Burnett, Alan Kenneth and Mills, K. I. 2000. An in vivo and in vitro comparison of the effects of b2-a2 and b3-a2 p210BCR-ABL splice variants on murine 32D cells. Leukemia and Lymphoma 37 (3-4) , pp. 393-404. 10.3109/10428190009089440

Baines, Paul, Fisher, J., Truran, L., Davies, E., Hallett, M., Hoy, T. and Burnett, Alan Kenneth 2000. The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro. European Journal of Haematology 64 (4) , pp. 211-218. 10.1034/j.1600-0609.2000.90139.x

Burnett, Alan Kenneth and Kell, Jonathan 2000. High dose cytarabine or transplantation for consolidation of younger patients with acute myeloid leukemia [review]. Current Opinion in Oncology 12 (2) , pp. 110-115. 10.1097/00001622-200003000-00002

Mills, K. I., Walsh, V., Gilkes, Amanda F., Sweeney, Marion Carol, Mirza, T., Woodgate, Louise, Brown, G. and Burnett, Alan Kenneth 2000. High FUS/TLS expression in acute myeloid leukaemia samples. British Journal of Haematology 108 (2) , pp. 316-321. 10.1046/j.1365-2141.2000.01883.x

McGlynn, Angela P., Padua, Rose Ann, Burnett, Alan Kenneth and Darley, Richard Lawrence 2000. Alternative effects of RAS and RAF oncogenes on the proliferation and apoptosis of factor-dependent FDC-P1 cells. Leukemia Research 24 (1) , pp. 47-54. 10.1016/s0145-2126(99)00159-9

Darley, Richard Lawrence, Pearn, Lorna and Burnett, Alan Kenneth 2000. Mutant RAS promotes amplification of primitive human erythroid cells. Blood 96 (11) , 92A-92A.

Dorak, M. Tevfik, Burnett, Alan Kenneth, Worwood, Mark, Sproul, Anne M. and Gibson, Brenda E. S. 1999. The C282Y mutation of HFE is another male-specific risk factor for childhood acute lymphoblastic leukemia [Letter]. Blood 94 (11) , pp. 3957-3958.

Darley, Richard Lawrence and Burnett, Alan Kenneth 1999. Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors. Experimental Hematology 27 (11) , pp. 1599-1608. 10.1016/S0301-472X(99)00100-9

Mills, Kenneth Ian, Woodgate, Louise, Gilkes, Amanda F., Walsh, V., Sweeney, Marion Carol, Brown, G. and Burnett, Alan Kenneth 1999. Inhibition of mitochondrial function in HL60 cells is associated with an increased apoptosis and expression of CD14. Biochemical and Biophysical Research Communications 263 (2) , pp. 294-300. 10.1006/bbrc.1999.1356

Dorak, M. Tevfik, Lawson, T., Machulla, H. K., Darke, C., Mills, K. I. and Burnett, Alan Kenneth 1999. Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. Blood 94 (2) , pp. 694-700.

Burnett, Alan 1999. Tailoring the treatment of acute myeloid leukemia. Current Opinion in Hematology 6 (4) , pp. 247-252.

Burnett, Alan Kenneth 1999. Treatment of acute myeloid leukemia [Letter]. New England Journal of Medicine 340 (18) , pp. 1438-1439. 10.1056/NEJM199905063401813

Allford, S., Grimwade, D., Langabeer, S., Duprez, E., Saurin, A., Chatters, S., Walker, Helen, Roberts, P., Rogers, J., Bain, B., Patterson, K., McKernan, A., Freemont, P., Solomon, E. and Burnett, Alan Kenneth 1999. Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. British Journal of Haematology 105 (1) , pp. 198-207. 10.1046/j.1365-2141.1999.01312.x

Austin, S. J., Robinson, L. G., Owen-Jones, Catrin E., Mills, Kenneth Ian and Burnett, Alan 1999. Quantitation of AML1-ETO fusion transcripts in t(8;21) positive AML using real-time light cycler PCR [Abstract]. British Journal of Haematology 105 , p. 76.

Woodgate, Louise J., Walker, E. J., Mills, Kenneth I. and Burnett, Alan Kenneth 1999. A comparison of differential display and atlas cDNA array for the elucidation of differential gene expression [Abstract]. British Journal of Haematology 105 , p. 75.

Mills, Kenneth Ian, Walsh, Valerie, Gilkes, Amanda F., Woodgate, Louise J. and Burnett, Alan Kenneth 1999. Inhibitors of mitochondrial function in HL60 cells induce CD14 prior to CD38 [Abstract]. British Journal of Haematology 105 (Sup.1) , p. 77.

Dorak, M. Tevfik, Mills, Kenneth Ian and Burnett, Alan Kenneth 1999. MHC class III polymorphisms in childhood acute lymphoblastic leukaemia [Abstract]. British Journal of Haematology 105 (Sup.1) , p. 68.

Woodgate, Louise J., Walker, E. J., Gilkes, Amanda F., Walsh, V., Sweeney, Marion Carol, Mills, Kenneth I. and Burnett, Alan 1999. Lovastatin in combination with ATRA may be a potential therapy for leukaemia [Abstract]. British Journal of Haematology 105 (Sup.) , p. 74.

Robinson, L. G., Owen-Jones, Catrin Eleri, Austin, Steve, Mills, Kenneth Ian and Burnett, Alanm Kenneth 1999. Relationship between PCR status following chemotherapy and outcome in t(8;21) positive acute myeloid leukaemia [Abstract]. British Journal of Haematology 105 (Sup.1) , p. 67.

Davies, C. S., Plass, C., Simrigalia, D., Mills, K. I. and Burnett, Alan Kenneth 1999. The detection of aberrant DNA methylation in chronic myeloid leukaemia using restriction landmark genome scanning. British Journal of Haematology 105 , p. 34.

Dorak, M. T., Burnett, Alan Kenneth and Worwood, M. 1999. The frequency of C282Y mutation in the HFE gene in newborns and in childhood acute lymphoblastic leukaemia. British Journal of Haematology 105 , p. 76.

Grimwade, D., Walker, H., Oliver, F., Chatters, S., Harrison, G., Wheatley, K., Burnett, Alan Kenneth and Goldstone, A. H. 1999. The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial. British Journal of Haematology 105 , p. 67.

Mills, K. I., Gilkes, A. F., Walsh, V., Sweeney, M., Woodgate, L. J., Mirza, T. and Burnett, Alan Kenneth 1999. The over-expression of the oncogene FUS (TLS) in AML patients may inhibit neutrophil differentiation. British Journal of Haematology 105 , p. 77.

Owen-Jones, Catrin, Robinson, L. G., Austin, Steve, Bailey-Wood, R., Agar, A., Mills, K. and Burnett, Alan Kenneth 1999. Absence of leukaemic cell contamination of bone marrow (BM) and peripheral blood stem cell (PBSC) harvests as detected by PCR in good risk Acute Myeloid Leukaemia. British Journal of Haematology 105 (Supp 1) , p. 56.

Robinson, L. G., Austin, Steve, Owen-Jones, Catrin Eleri, Kell, J., Gilkes, Amanda, Dann, E., Mills, K. and Burnett, Alan Kenneth 1999. Altered gene expression in 32D cells expressing the AML1A gene or AML1-ETO fusion gene. British Journal of Haematology 105 (Supp1) , p. 103.

Brown, S. A., Davies, S. V., Fegan, Christopher Daniel, West, Robert Raynard, Giddings, J., Whittaker, J. and Burnett, Alan Kenneth 1999. Haemostatic and fibrinolytic responses to bone marrow transplantation. British Journal of Haematology 104 (3) , pp. 468-474. 10.1046/j.1365-2141.1999.01223.x

Pallis, M., Turzanski, J., Harrison, G., Wheatley, K., Langabeer, S., Burnett, Alan Kenneth and Russell, N. H. 1999. Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia. British Journal of Haematology 104 (2) , pp. 307-312. 10.1046/j.1365-2141.1999.01157.x

Burnett, Alan 1999. Tailoring the treatment of acute myeloid leukemia. Current Opinion in Oncology 11 (1) , pp. 14-19.

Wheatley, Keith, Burnett, Alan Kenneth, Goldstone, Anthony H., Gray, Richard G., Hann, Ian M., Harrison, Christine J., Rees, John K. H., Stevens, Richard F. and Walker, Helen 1999. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. British Journal of Haematology 107 (1) , pp. 69-79. 10.1046/j.1365-2141.1999.01684.x

Lowenberg, Bob, Downing, James R. and Burnett, Alan Kenneth 1999. Acute Myeloid Leukemia. New England Journal of Medicine 341 (14) , pp. 1051-1062. 10.1056/NEJM199909303411407

Burnett, Alan, Grimwade, David, Solomon, Ellen, Wheatley, Keith and Goldstone, Anthony H. 1999. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 93 (12) , pp. 4131-4143.

Watson, Maggie, Wheatley, Keith, Harrison, Georgina A., Zittoun, Robert, Gray, RIchard G., Goldstone, Alan H. and Burnett, Alan Kenneth 1999. Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone. Cancer 86 (7) , pp. 1231-1239. 10.1002/(SICI)1097-0142(19991001)86:7<1231::AID-CNCR18>3.0.CO;2-Y

Burnett, Alan Kenneth 1998. Transplantation in first remission of acute myeloid leukemia [Editorial]. New England Journal of Medicine 339 (23) , pp. 1698-1700. 10.1056/NEJM199812033392309

Mills, Kenneth Ian, Gilkes, Amanda, Sweeney, Marion, Choudhry, M. A., Woodgate, Louise, Bunce, C. M., Brown, G. and Burnett, Alan Kenneth 1998. Identification of a retinoic acid responsive aldoketoreductase expressed in HL60 leukaemic cells. FEBS Letters 440 (1-2) , pp. 158-162. 10.1016/s0014-5793(98)01435-5

Austin, Steve J., Robinson, L. G., Owen-Jones, Catrin Eleri, Mills, Kenneth Ian and Burnett, Alan Kenneth 1998. Real-time PCR (lightcycler technology) for quantitation of AML1-ETO fusion transcripts in t(8;21) positive AML. Blood 92 (10) , 75A-75A.

Truran, Louise N., Kell, J., Nicholson, D., Hoy, T. G. and Burnett, Alan Kenneth 1998. Quantitative bax expression correlates with response to treatment in AML. Blood 92 (10) , 218A-218A.

Mills, K. I., Mirza, T., Gilkes, A. F., Walsh, V., Sweeney, M. C., Woodgate, L. J. and Burnett, Alan Kenneth 1998. The proto-oncogene FUS is specifically down-regulated during neutrophil differentiation. Blood 92 (10) , 194A-194A.

Grimwade, David, Walker, Helen, Oliver, Fiona, Wheatley, Keith, Harrison, Christine, Harrison, Georgina, Rees, John, Hann, Ian, Stevens, Richard, Burnett, Alan Kenneth and Goldston, Anthony 1998. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92 (7) , pp. 2322-2333.

Mills, K. I., Walsh, V., Gilkes, Amanda, Woodgate, Louise, Brown, G. and Burnett, Alan Kenneth 1998. Identification of transcription factors expressed during ATRA-induced neutrophil differentiation of HL60 cells. British Journal of Haematology 103 (1) , pp. 87-92. 10.1046/j.1365-2141.1998.00947.x

Burnett, Alan Kenneth, Goldstone, A., Hann, I., Stevens, R., Rees, J. K. H. and Wheatley, K. 1998. Evaluation of stem cell transplantation in AML. Leukemia and Lymphoma 30 , p. 29. 10.3109/10428199809058623

Robinson, L. G., Austin, S. J., Owen-Jones, Catrin Eleri, Al-Sabah, Ayesha, Bailey-Wood, R., Mills, K. I. and Burnett, Alan Kenneth 1998. Prognostic value of IgH rearrangement detection in peripheral blood stem cell (PBSC) harvests of patients with Multiple Myeloma undergoing PBSC transplantation [Abstract]. British Journal of Haematology 102 (1) , pp. 292-293. 10.1111/j.1365-2141.1998.tb08997.x

Darley, Richard Lawrence, Hoy, T. G., Robinson, L. and Burnett, Alan Kenneth 1998. Mutant N-RAS blocks granulocytic differentiation of human cd34+ cells. British Journal of Haematology 102 (1) , p. 289. 10.1111/j.1365-2141.1998.tb08997.x

Padua, RA, Parrado, A, Jordan, D, Bastard, C, McKenna, S, Whittaker, J, Bentley, P, Burnett, Alan Kenneth and Chomienne, C 1998. Screening for retinoic acid receptor alpha (RAR alpha) rearrangements in non-APL identifies a novel fusion gene in CMML. British Journal of Haematology 102 (1) , p. 33. 10.1111/j.1365-2141.1998.tb08995.x

Baines, Paul, Lake, Helen, Fisher, Janet, Truran, Louise, Hoy, Terry and Burnett, Alan Kenneth 1998. Overgrowth of a leukemic culture by a minor CD34+ population. Leukemia Research 22 (6) , pp. 549-556. 10.1016/S0145-2126(98)00043-5

Woodgate, Louise J., Walker, E. J., Gilkes, Amanda F., Walsh, V., Mills, Kenneth Ian and Burnett, Alan Kenneth 1998. Lovastatin in combination with ATRA partially overcomes the block in ATRA responsiveness of the serum independent HL60 cell line [Abstract]. British Journal of Haematology 101 (S) , p. 34.

Langabeer, S. E., Grimwade, D., Walker, H., Rogers, J. R., Burnett, Alan Kenneth, Goldstone, A. H. and Linch, D. C. 1998. A study to determine whether trisomy 8, deleted 9q and trisomy 22 are markers of cryptic rearrangements of PML/RARalpha, AML1/ETO and CBFB/MYH11 respectively in acute myeloid leukaemia. British Journal of Haematology 101 (2) , pp. 338-340. 10.1046/j.1365-2141.1998.00686.x

Kell, W. J. and Burnett, Alan Kenneth 1998. 5-aza-2 '-deoxycytidine in myelodysplasia [Abstract]. British Journal of Haematology 101 (S) , p. 64.

Kell, W. J., Hofmann, W. K., Hoelzer, D., Chomienne, C., Ganser, A., Fenaux, P., Castaigne, S., Burnett, R. and Burnett, Alan Kenneth 1998. 9-cis-retinoic acid treatment for myelodysplasia [Abstract]. British Journal of Haematology 101 (S) , p. 64.

Dorak, M. T., Lawson, T., Machulla, H. K. G., Parsons, A., Mills, K. I. and Burnett, Alan Kenneth 1998. A male-specific HLA association in childhood leukaemia [Abstract]. British Journal of Haematology 101 (S) , p. 35.

Woodgate, Louise J., Gilkes, Amanda F., Newsway, Vicky, Mills, K. I. and Burnett, Alan Kenneth 1998. Mitochondrial inhibitors may act as promoters of differentiation in the serum free HL60 cell line [Abstract]. British Journal of Haematology 101 (S) , p. 34.

Robinson, L. G., Austin, S. J., Owen-Jones, Catrin Eleri, Langabeer, S. E., Linch, D. C., Mills, K. I. and Burnett, Alan 1998. Multiplex PCR for the detection of prognostically important gene rearrangements in acute myeloid leukaemia [Abstract]. British Journal of Haematology 101 (S) , p. 21.

Darley, Richard Lawrence, Hoy, T. G. and Burnett, Alan Kenneth 1998. Mutant N-RAS blocks granulocytic differentiation of human CD34(+) cells [Abstract]. British Journal of Haematology 101 (S) , p. 22.

Padua, R. A., Parrado, A., West, R., Jordan, D., Bastard, C., McKenna, S., Whittaker, J., Bentley, P., Burnett, Alan Kenneth and Chomienne, C. 1998. Retinoic acid receptor alpha (RAR alpha) gene rearrangements in non-acute promyelocytic leukaemia (non-APL) [Abstract]. British Journal of Haematology 101 , p. 39.

Mills, K. E., Gilkes, A. F., Sweeney, M., Woodgate, L. J., Choudhry, M. A., Bunce, C. M., Brown, G. and Burnett, Alan 1998. The identification of a retinoic acid responsive aldo-keto-reductase expressed during neutrophil and monocyte differentiation of HL60 cells. British Journal of Haematology 101 , p. 34.

Mirza, T., Gilkes, A. F., Woodgate, L. J., Mills, K. I. and Burnett, Alan Kenneth 1998. The proto-oncogene FUS is down regulated within on hour of ATRA treatment of HL60 cells. British Journal of Haematology 101 , p. 22.

Grimwade, D., Langabeer, S., Howe, K., Walker, H., Wheatley, K., Harrison, G., Goldstone, A., Burnett, Alan Kenneth and Solomon, E. 1998. The role of molecular diagnosis & residual disease monitoring in APL: Results of the MRC ATRA trial. British Journal of Haematology 101 , p. 103.

Langabeer, S. E., Allford, S., Grimwade, D., Chatters, S. J., Walker, H., Oliver, F. J., Rogers, J. R., Arnold, J., Bain, B. J., Kilby, A. M., Goldstone, A. H., Burnett, Alan Kenneth, Patterson, K. G. and Linch, D. C. 1998. Two cases of t(15;17) not associated with APL and the value of molecular screening for PML/RAR alpha in AML. British Journal of Haematology 101 , p. 31.

Burnett, Alan Kenneth, Goldstone, Anthony H., Stevens, Richard M. F., Hann, Ian M., Rees, John K. H., Gray, Richard G. and Wheatley, Keith 1998. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. The Lancet 351 (9104) , pp. 700-708. 10.1016/S0140-6736(97)09214-3

Truran, Louise, Baines, Paul, Hoy, Terry and Burnett, Alan Kenneth 1998. GCSF augments post-progenitor proliferation in serum-free cultures of myelodysplastic marrow while ATRA enhances maturation. Leukemia Research 22 (3) , pp. 241-248. 10.1016/s0145-2126(97)00179-3

Brown, S. A., Goringe, A., Fegan, Christopher Daniel, Davies, S. V., Giddings, John Charles, Whittaker, J. A., Burnett, Alan Kenneth and Poynton, Christopher Hilton 1998. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplantation 22 (3) , pp. 281-284. 10.1038/sj.bmt.1701321

Gallagher, Andrea P., Burnett, Alan Kenneth, Bowen, David T. and Darley, Richard Lawrence 1998. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process. Cancer Research 58 (9) , pp. 2029-2035.

Burnett, Alan Keith, C lough, ., G rundy, ., H olme, ., L achmann, ., M arshall, ., S cott, ., S kacel, ., S inclair, ., T aylor, . and W alsh, . 1998. Royal College of Physicians of Edinburgh consensus conference on platelet transfusion. Transfusion Medicine 8 (2) , pp. 149-151. 10.1046/j.1365-3148.1998.00140.x

Grimwade, D., Gorman, P., Duprez, E., Howe, K., Langabeer, S., Oliver, F., Walker, H., Culligan, D., Waters, J., Pomfret, M., Goldstone, A., Burnett, Alan Kenneth, Freemont, P., Sheer, D. and Solomon, E. 1997. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 90 (12) , pp. 4876-4885.

Langabeer, S. E., Walker, Helen, Rogers, J. R., Burnett, Alan Kenneth, Wheatley, K., Swirsky, D., Goldstone, A. H. and Linch, D. C. 1997. Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. British Journal of Haematology 99 (4) , pp. 925-928. 10.1046/j.1365-2141.1997.4663270.x

Austin, Steve, Robinson, L. J., Owen Jones, Catrin Eleri, Langabeer, S. E., Linch, D. C., Mills, K. I. and Burnett, Alan Kenneth 1997. Multiplex PCR detection of 11q23 abnormalities in acute myeloid leukaemia [Abstract]. Blood 90 (10) , p. 3666.

Woodgate, Louise, Gilkes, Amanda F., Newsway, V., Mills, Kenneth Ian and Burnett, Alan Kenneth 1997. Mitochondrial inhibitors as differentiation agents in the myeloid HL60 cell line [Abstract]. Blood 90 (10) , p. 3801.

Robinson, L.G., Owen-Jones, Catrin Eleri, Bowen, D, Langabeer, S.E., Linch, D.C., Mills, Kenneth Ialn and Burnett, Alan Kenneth 1997. Multiplex PCR for the detection of prognostically important chromosomal abnormalities in acute myeloid leukaemia [Abstract]. Blood 90 (10) , p. 276.

Darley, Richard Lawrence, Gallagher, A. P., Bowen, D. T. and Burnett, Alan Kenneth 1997. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a PKC-dependent process. Blood 90 (10) , p. 202.

Mills, KI, Walsh, Val, Guinn, B. A., Gilkes, Amanda F., Davies, C., Lee Jones, L., Goringe, A., Evely, R. S. and Burnett, Alan Kenneth 1997. Increased tissue infiltration and decreased survival of SCID mice injected with 32D cells expressing BCR-ABL mRNA may be related to increased expression of CD44 and RHAMM [Abstract]. Blood 90 (10) , p. 4005.

Grimwade, D., Langabeer, S., Gorman, P., Howe, K., Duprez, E., Walker, Helen, Wheatley, K., Goldstone, A., Burnett, Alan Kenneth and Solomon, E. 1997. Molecular characterisation of patients with APL entered into the UK MRC ATRA trial: Relationship of PML breakpoint with additional cytogenetic abnormalities and outcome [Abstract]. Blood 90 (10) , p. 271.

Mills, K. I., Walsh, V., Gilkes, A. F., Woodgate, L. J. and Burnett, Alan Kenneth 1997. The altered expression of sequences containing zinc finger and POU homeodomain motifs from HL60 cultures during neutrophil differentiation induction with ATRA and vitamin D3. Blood 90 (10) , p. 3417.

Mills, K. I., Mirza, T., Gilkes, A. F., Woodgate, L. J. and Burnett, Alan Kenneth 1997. The proto-oncogene FUS is down-regulated within one hour of ATRA treatment of HL60 cells. Blood 90 (10) , p. 187.

Burnett, Alan Kenneth, Wheatley, K., Langabeer, S., Walker, Helen, Linch, D., Goldstone, A. H., Hann, I. and Stevens, R. F. 1997. Outcome of acute myeloid leukaemias affecting core binding factor subunits: the UK MRC experience. Blood 90 (10) , p. 1737.

Goldstone, A. H., Burnett, Alan Kenneth, Milligan, D. W., Prentice, A. G. and Wheatley, K. 1997. Lack of benefit of G-CSF on complete remission and possible increased relapse risk in AML: An MRC study of 800 patients [Abstract]. Blood 90 (10) , p. 2595.

McGlynn, H., Kapelko, K., Baker, A., Burnett, Alan Kenneth and Padua, R. A. 1997. Allelic loss of the FMS gene in acute myeloid leukaemia. Leukemia Research 21 (10) , pp. 919-923. 10.1016/s0145-2126(97)00024-6

Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Clack, R., Burnett, Alan Kenneth and Goldstone, A. 1997. What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Bone Marrow Transplantation -Basingstoke then London- 19 (11) , pp. 1117-1123.

Masters, Gillian S. and Burnett, Alan Kenneth 1997. Serum-free culture of human megakaryocyte progenitors. Clinical and Laboratory Haematology 19 (1) , pp. 61-65. 10.1046/j.1365-2257.1997.00193.x

Rees, D., Grimwade, D., Langabeer, S., Burnett, Alan Kenneth and Goldstone, A. 1997. Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia. British Journal of Haematology 96 (3) , pp. 490-492. 10.1046/j.1365-2141.1997.d01-2063.x

Langabeer, S. E., Walker, Helen, Gale, R., Wheatley, K., Burnett, Alan Kenneth, Goldstone, A. H. and Linch, D. C. 1997. Frequency of CBFβ/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. British Journal of Haematology 96 (4) , pp. 736-739. 10.1046/j.1365-2141.1997.d01-2096.x

Burnett, Alan Kenneth and Eden, O. B. 1997. The treatment of acute leukaemia. The Lancet 349 (9047) , pp. 270-275. 10.1016/S0140-6736(96)08086-5

Zaker, Farhad, Darley, Richard Lawrence, Sabah, Ala Al and Burnett, Alan Kenneth 1997. Oncogenic RAS genes impair erythroid differentiation of erythroleukaemia cells. Leukemia Research 21 (7) , pp. 635-640. 10.1016/S0145-2126(97)00022-2

Ramsahoye, B., Burnett, Alan Kenneth and Taylor, C. 1997. Restriction endonuclease isoschizomers ItaI, BsoFI and Fsp4HI are characterised by differences in their sensitivities to CpG methylation. Nucleic Acids Research 25 (16) , pp. 3196-3198. 10.1093/nar/25.16.3196

Darley, Richard Lawrence, Hoy, Terence G., Baines, Paul, Padua, Rose Ann and Burnett, Alan Kenneth 1997. Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ Cells. Journal of Experimental Medicine 185 (7) , pp. 1337-1348. 10.1084/jem.185.7.1337

Tennant, G. B., Truran, Louise N., Kell, W. J. and Burnett, Alan Kenneth 1997. Myelodysplastic bone marrow stroma is defective in its ability to sustain normal stem cell growth. Blood 90 (10) , p. 2589.

Brown, S. A., Davies, S. V., Giddings, John Charles and Burnett, Alan Kenneth 1997. Study of markers of thrombin and plasmin generation during bone marrow transplantation. Thrombosis And Haemostasis 78 (Supp S) , PS509-PS509.

Zaker, F., May, A., Al-Sabah, AIa and Burnett, Alan Kenneth 1996. A novel model for differentiation therapy of leukaemia [Abstract]. British Journal of Haematology 93 (S2) , p. 43. 10.1111/j.1365-2141.1996.tb08988.x

Tennant, G. B., Truran, Louise N. and Burnett, Alan Kenneth 1996. Reduced growth of normal myeloid progenitors on MDS stroma is unrelated to confluence. British Journal of Haematology 93 (S2) , p. 66. 10.1111/j.1365-2141.1996.tb08988.x

Brown, S. A., Davies, S. V., Fegan, Christopher Daniel, Ralis, H., Giddings, John Charles, Poynton, Christopher Hilton, Whittaker, J. A. and Burnett, Alan Kenneth 1996. A biphasic haemostatic response during bone marrow transplantation [Abstract]. Blood 88 (10) , p. 1638.

White, A. D., Jones, B. M., Worwood, Mark, Webb, D. K. H., Davies, K. R., Clark, V. and Burnett, Alan Kenneth 1996. Monitoring disease status in paediatric acute lymphoblastic leukemia (ALL) using conventional cytogenetic techniques, fluorescence in situ hybridisation (FISH) and PCR detection of IgH gene rearrangements (CDR3) [Abstract]. Blood 88 (10) , p. 285.

Woodgate, L. J., Walsh, V., Gilkes, A., Mills, K. I. and Burnett, Alan Kenneth 1996. The isolation of gene specific family members from HL60 variant cultures after differentiation induction with ATRA and vitamin D-3. Blood 88 (10) , p. 3174.

Mills, K. I., Guinn, B. A., Walsh, V. A. and Burnett, Alan Kenneth 1996. Increasing methylation of the calcitonin gene during disease progression in sequential samples from CML patients. Leukemia Research 20 (9) , pp. 771-775. 10.1016/0145-2126(96)00045-8

Darley, Richard Lawrence, Baines, Paul, Hoy, Terence G., Padua, Rose Ann and Burnett, Alan Kenneth 1996. Mutant N-RAS alters the developmental potential of human CD34(+) cells in a lineage-specific manner. British Journal of Haematology 93 (S2) , p. 597.

Baines, P., Fisher, J., Hoy, T., Truran, L. and Burnett, Alan Kenneth 1996. In-vitro differentiation of AML blasts. British Journal of Haematology 93 , p. 250.

Evely, R. S., Darley, Richard Lawrence, Gilkes, Amanda F., Goringe, A., Mirza, T. and Burnett, Alan Kenneth 1996. In-vivo modelling of myeloid malignancies using severe combined immunodeficient (SCID) mice [Abstract]. British Journal of Haematology 93 , p. 205.

Tennant, Graham Burt, Truran, L. N. and Burnett, Alan 1996. Normal haemopoietic progenitors grow better on stromal layers from normal, rather than myelodysplastic, marrow [Abstract]. British Journal of Haematology 93 (S1) , p. 1. 10.1111/j.1365-2141.1996.tb08965.x

Al-Sabah, A., Wynn, R., O'Callaghan, U., Lim, S., Whittaker, J. A., Poynton, Christopher Hilton and Burnett, Alan Kenneth 1996. Quadruple transplant for myeloma: a study of feasibility [Abstract]. British Journal of Haematology 93 (Sup.) , p. 314.

Lee-Jones, L., Hoy, T., Mills, K. I. and Burnett, Alan Kenneth 1996. The identification of genetic regions involved in chemical induced leukaemia [Abstract]. British Journal of Haematology 93 (S1) , p. 19.

Coleman, S., Fisher, Janet, Hoy, Terence George, Burnett, Alan Kenneth and Lim, Seah H. 1996. Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia. Leukemia 10 (3) , pp. 483-487.

Ramsahoye, B. H., Burnett, Alan Kenneth and Taylor, C. 1996. Nucleic acid composition of bone marrow mononuclear cells in cobalamin deficiency. Blood 87 (5) , pp. 2065-2070.

Worwood, Mark, Evans, W. D., Villis, R. J. and Burnett, Alan kenneth 1996. Iron absorption from a natural mineral water (Spatone Iron-Plus). Clinical and Laboratory Haematology 18 (1) , pp. 23-27. 10.1111/j.1365-2257.1996.tb00732.x

Porwit Macdonald, A., Janossy, G., Ivory, K., Swirsky, D., Peters, R., Wheatley, K., Walker, H., Turker, A., Goldstone, A. H. and Burnett, Alan Kenneth 1996. Leukemia-associated changes identified by quantitative flow cytometry .4. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood 87 (3) , pp. 1162-1169.

Dorak, M. Tevfik, Machulla, Helmut K. G., Hentschel, Michael, Mills, Kenneth Ian, Langner, Jürgen and Burnett, Alan Kenneth 1996. Influence of the major histocompatibility complex on age at onset of chronic lymphoid leukaemia. International Journal of Cancer 65 (2) , pp. 134-139.

Dorak, M. Trevfik, Darke, C., Machulla, H. K. G., Mills, Kenneth Ian and Burnett, Alan Kenneth 1996. A gender effect in HLA association with childhood leukemia. Human Immunology 49 (S1) , p. 64. 10.1016/S0198-8859(96)80030-9

Stephens, Mark William, Talary, M. S., Pethig, R., Burnett, Alan Kenneth and Mills, Ken Ian 1996. The dielectrophoresis enrichment of CD34+ cells from peripheral blood stem cell harvests. Bone Marrow Transplant 18 (4) , pp. 777-782.

Dorak, M. Tevfik, McKinna, F., Schaaf, A., Machulla, H. K. G., Darke, C., Burnett, Alan Kenneth and Barrett-Lee, Peter 1996. Major histocompatibility complex and breast cancer. Human Immunology 49 (S 1) , pp. 11-22. 10.1016/S0198-8859(96)80042-5

Grimwade, D., Howe, K., Langabeer, S, Burnett, Alan Kenneth, Goldstone, A. and Solomon, E. 1996. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia 10 (1) , pp. 61-66.

Lim, Seah H., Culligan, Dominic, Couzens, Stephen, Fisher, Janet, John, Susan, Pollard, Peter, Burnett, Alan Kenneth and Whittaker, Jack 1996. Molecular evidence for a common leukaemic progenitor in acute mixed lymphoid and myeloid leukaemia. British Journal of Haematology 92 (1) , pp. 131-133. 10.1046/j.1365-2141.1996.281821.x

Mills, K. I., Guinn, B. A., Walsh, V., Gilkes, A. F., Lee-Jones, L., Francis, D., Evans, S. and Burnett, Alan Kenneth 1996. The cellular, morphological and molecular characteristics of a murine cell line model of CML [Abstract]. British Journal of Haematology 93 (S2) , p. 71.

Lee-Jones, L., Hoy, T., Mills, K. I. and Burnett, Alan Kenneth 1996. The identification, by ALU-PCR, of genetic regions involved in chemical induced leukaemia [Abstract]. British Journal of Haematology 93 (S2) , p. 65.

Wheatley, K., Burnett, Alan Kenneth, Goldstone, A. H., Hann, I. M., Stevens, R. C., Rees, J. K. and Gray, R. G. 1995. A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial [Abstract]. Blood 86 (10) , p. 2381.

Grimwade, D., Howe, K., Langabeer, S., Walker, Helen, Smith, F., Swirsky, D., Wheatley, K., Goldstone, A., Burnett, Alan Kenneth and Solomon, E. 1995. Molecular and cytogenetic assessment of patients with acute promyelocytic leukaemia (APL) entered into the UK MRC ATRA trial [Abstract]. Blood 86 (10) , p. 1060.

Mills, K. I., Guinn, B. A., Evely, R. S., Walsh, V., Gilkes, A. F., LeeJones, L., Barnes, N. and Burnett, Alan Kenneth 1995. The effect of BCR-ABL splice type on engraftment in SCID mice, and gene expression. Blood 86 (10) , p. 2389.

Woodgate, L. J., Mizra, T., Newsway, V., Gilkes, A., Taylor, C., Mills, K., Burnett, Alan Kenneth, Brown, G. and Bunce, V. 1995. The identification of differentially expressed genes in the serum independent cell line HL60, upon differentiation induction. Blood 86 (10) , p. 3210.

Gallagher, A., Padua, R. A., Al-Sabah, A., Hoy, T., Burnett, Alan Kenneth and Darley, R. L. 1995. Aberrant expression of p21RAS but not p120GAP is a common feature of myelodysplasia. Leukemia 9 (11) , pp. 1833-1840.

Guinn, B. A., Smith, Melissa, Padua, R. A., Burnett, Alan Kenneth and Mills, K. 1995. Changing p53 mutations with the evolution of chronic myeloid leukaemia from the chronic phase to blast crisis. Leukemia Research 19 (8) , pp. 519-525. 10.1016/0145-2126(95)00024-i

Masters, Gillian S., Baines, Paul, Tang, Carol, Bowen, David and Burnett, Alan Kenneth 1995. Responsiveness to stem cell factor (SCF) of peripheral blood colony-forming cells from patients with myelodysplastic syndromes (MDS). Leukemia Research 19 (8) , pp. 561-566. 10.1016/0145-2126(95)00034-L

Coleman, Sharon Louise, Perera, P., Fisher, Janet, Hoy, Terry, Burnett, Alan Kenneth and Lim, S. H. 1995. Abnormal TCR V/3 repertoire in patients with chronic myeloid leukaemia. British Journal of Haematology 90 (2) , pp. 358-363. 10.1111/j.1365-2141.1995.tb05159.x

Raha-Chowdhury, R., Bowen, Derrick John, Burnett, Alan Kenneth and Worwood, Mark 1995. Allelic associations and homozygosity at loci from HLA-B to D6S299 in genetic haemochromatosis. Journal of Medical Genetics 32 (6) , pp. 446-452. 10.1136/jmg.32.6.446

Talary, M. S., Mills, Kenneth Ian, Hoy, T., Burnett, Alan Kenneth and Pethig, R. 1995. Dielectrophoretic separation and enrichment of CD34+ cell subpopulation from bone marrow and peripheral blood stem cells. Medical and Biological Engineering and Computing 33 (2) , pp. 235-237. 10.1007/bf02523050

Culligan, Dominic J., Bowen, David T., May, Alison, White, Denise, Padua, Rose Ann and Burnett, Alan Kenneth 1995. Refractory anaemia with preleukaemic polyclonal haemopoiesis and the emergence of monoclonal erythropoiesis on disease progression. British Journal of Haematology 89 (3) , pp. 675-677. 10.1111/j.1365-2141.1995.tb08389.x

Dorak, M. Tevfik, Wilson, David W. L., Galbraith, Ian, Henderson, Nancy, Burnett, Alan Kenneth and Worwood, Mark 1995. A molecular analysis of the telomeric end of the major histocompatibility complex: DNA typing of HLA-A3 subtypes and -B7. Human Immunology 42 (1) , pp. 1-8. 10.1016/0198-8859(94)00054-T

Baker, A. H., Ball, S., McGlynn, H., Whittaker, J. A., Burnett, Alan Kenneth and Padua, R. A. 1995. A C-terminal FMS mutation in a patient with B-cell malignancy. Leukemia 9 (1) , pp. 155-158.

Darley, Richard Lawrence, Baines, Paul, Hoy, T. G. and Burnett, Alan Kenneth 1995. Mutant N-RAS induces erythroid lineage dysplasia in human CD34(+) progenitor cells. Blood 86 (10) , p. 1665.

Baker, A. H., Cachia, P. G., Tennant, Graham Burt, Whittaker, J. A., White, D, Stanley, E. R., Burnett, Alan Kenneth and Padua, R. A. 1995. A novel CSF-1 binding factor in a patient in complete remission following cytotoxic therapy for lymphoma. British Journal of Haematology 89 (1) , pp. 219-222. 10.1111/j.1365-2141.1995.tb08937.x

Burnett, Alan Kenneth 1994. Karyotypically defined risk groups in acute myeloid leukaemia. Leukemia Research 18 (12) , pp. 889-890. 10.1016/0145-2126(94)90099-X

Gallagher, A., Padua, R. A., Alsabah, A., Burnett, Alan Kenneth and Darley, Richard Lawrence 1994. P21RAS expression in leukemogenesis and hematopoiesis. Blood 84 (10) , A605-A605.

Poynton, Christopher H., Fegan, Christopher Daniel, Al-Sabah, Ali I., Couzens, Stephen, John, S., Hoy, Terence George, White, D. and Burnett, Alan Kenneth 1994. Aberrant durface phenotype in MDS confers a poor-prognosis with more rapid development of AML [Abstract]. Blood 84 (10) , A316.

Guinn, Barbara-Ann, Padua, Rose Ann, Burnett, Alan Kenneth and Mills, Ken 1994. P53 mutations indicate a changing clonal evolution in a portion of chronic myelocytic-leukemia patients [Letter]. Blood 84 (10) , p. 3591.

Baines, P., Truran, L., Bailey-Wood, R., Hoy, T., Lake, H., Poynton, Christopher H. and Burnett, Alan Kenneth 1994. Haemopoietic colony-forming cells from peripheral blood stem cell harvests: cytokine requirements and lineage potential. British Journal of Haematology 88 (3) , pp. 472-480. 10.1111/j.1365-2141.1994.tb05062.x

Dorak, M. Tevfik, Burnett, Alan Kenneth and Worwood, Mark 1994. Thymus-leukaemia antigens: The haemochromatosis gene product? Immunology and Cell Biology 72 (5) , pp. 435-439. 10.1038/icb.1994.64

Dorak, M. Trevfik, Mills, Kenneth Ian, Gaffney, D., Wilson, D. W., Galbraith, I., Henderson, N. and Burnett, Alan Kenneth 1994. Homozygous MHC genotypes and longevity. Human Heredity 44 (5) , pp. 271-278. 10.1159/000154229

Baines, P., Limaye, M., Hoy, T., Padua, R. A., Whittaker, Jack, al-Sabah, A. and Burnett, Alan Kenneth 1994. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations. Leukemia Research 18 (9) , pp. 683-691. 10.1016/0145-2126(94)90068-x

Worwood, Mark, Raha-Chowdhury, Ruma, Dorak, M. Tevfik, Darke, C., Bowen, Derrick John and Burnett, Alan Kenneth 1994. Alleles at D6S265 and D6S105 define a haemochromatosis-specific genotype. British Journal of Haematology 86 (4) , pp. 863-866. 10.1111/j.1365-2141.1994.tb04843.x

Cachia, P. G., Taylor, C., Thompson, P. W., Tennant, G. B., Masters, G., Pettersson, T., Whittaker, J. A., Burnett, Alan Kenneth, Jacobs, A. and Padua, R. A. 1994. Non-dysplastic myelodysplasia? Leukemia 8 (4) , pp. 677-681.

Dorak, M.Tevfik and Burnett, Alan Kenneth 1994. Molecular mimicry of an HLA-DR53 epitope by viruses. Immunology Today 15 (3) , pp. 138-139. 10.1016/0167-5699(94)90160-0

Guinn, B. A., Walsh, Valerie, Evely, R., Padua, R. A., Burnett, Alan Kenneth and Mills, Kenneth Ian 1994. Murine 32D cells expressing both B2-A2 and B3-A2 spliced BCR-ABL messenger-RNA have enhanced growth and engraftment characteristics. Blood 84 (10) , A138-A138.

Dorak, M. T., Chalmers, E. A., Gaffney, D., Wilson, D. W., Glabraith, I., Henderson, N., Worwood, Mark, Mills, K. I. and Burnett, Alan Kenneth 1994. Human major histocompatibility complex contains several leukemia susceptibility genes. Leukemia and Lymphoma 12 (3-4) , pp. 211-222. 10.3109/10428199409059592

Coiffier, B., Philip, T., Burnett, Alan Kenneth and Symann, M. L. 1994. Consensus conference on intensive chemotherapy plus hematopoietic stem cell transplantation in malignancies, Lyon, June 4-6, 1993 [review]. Annals of Oncology 5 (1) , pp. 19-23.

Padua, R. A., Cachia, P. G., Taylor, C., Thompson, P. W., Tennant, G. B., Masters, Gillian S., Pettersson, T., Whittaker, J. A. and Burnett, Alan Kenneth 1993. Non-dysplastic myelodysplasia (MDS). Blood 82 (10) , A555-A555.

Padua, R. A., Jordan, E. D., Conlon, F. V., Whittaker, J. A. and Burnett, Alan Kenneth 1993. Retinoic acid receptor alpha-gene rearrangements in myelodysplastic syndrome (MDS) and leukemia. Blood 82 (10) , A112-A112.

Bowen, D. T., Padua, R. A., Burnett, Alan Kenneth, deCastro, C. M. and Kaufman, R. E. 1993. Two new polymorphisms but no mutations of the KIT gene in patients with myelodysplasia at positions corresponding to human FMS and murine W locus mutational hot spots. Leukemia 7 (11) , pp. 1883-1885.

Tennant, G. B., Al-Sabah, AI, Culligan, D., Bowen, D. T., Jacobs, A. and Burnett, Alan Kenneth 1993. In-vitro response of myeloid progenitors to phytohaemagglutin and interleukin-2 is related to survival of some myelodysplastic patients [Abstract]. Experimental Hematology 21 (8) , p. 1036.

Baines, P., Limaye, M., Hoy, T., Padua, R. A., Whittaker, J. A. and Burnett, Alan Kenneth 1993. Role of P-glycoprotein in in-vitro drug-resistance in acutem myeloid and chronic lymphocytic leukemic blasts and in normal hematopoietic populations [Abstract]. Experimental Hematology 21 (8) , p. 1044.

Burnett, Alan Kenneth, Graham, S. and Alcorn, M. 1993. Sustained growth in long trm bone-marrow culture of AML remission marrow predicts a high probability of remaining relapse-free after auto BMT in first complete remission. Experimental Hematology 21 (8) , p. 1020.

Dorak, M. T., Raha-Chowdhury, R., Worwood, Mark, Mills, Kenneth I. and Burnett, Alan Kenneth 1993. A molecular investigation of homozygosity for HLA-A3 [Abstract]. British Journal of Haematology 84 (Sup.1) , p. 59. 10.1111/j.1365-2141.1993.tb06831.x

Guinn, B. A., Smith, M., Mills, Kenneth Ian, Burnett, Alan Kenneth and Padua, R. A. 1993. P53 abnormalities in leukemia and preleukemia [Abstract]. British Journal of Haematology 84 (Sup.1) , p. 36.

Dorak, M. Trevfik, Owen, G., Webb, D., Mills, Kenneth Ian and Burnett, Alan Kenneth 1993. Nature of HLA association in childhood acute lymphoblastic leukemia. Human Immunology 37 (S 1) , p. 65. 10.1016/0198-8859(93)90313-P

Dorak, M. Trevfik, Raha-Chowdhury, R., Owen, G., Worwood, Mark, Mills, K. I. and Burnett, Alan Kenneth 1993. A molecular analysis of HLA-A3 subtypes: Relevance to disease associations. Human Immunology 37 (S1) , p. 19. 10.1016/0198-8859(93)90221-L

Gale, R. E., Wheadon, H., Goldstone, A. H., Burnett, Alan Kenneth and Linch, D. C. 1993. Frequency of clonal remission in acute myeloid leukaemia. The Lancet 341 (8838) , pp. 138-142. 10.1016/0140-6736(93)90004-z

This list was generated on Sun Nov 17 05:06:46 2019 GMT.